MEK immunooncology inhibitors and therapeutic uses thereof

By designing a new dual MEK inhibitor with short half-life and cyclic activity inhibitory characteristics, the problems of existing MEK inhibitors in tolerance and drug resistance are solved, and deep circulation inhibition of the MAPK pathway and uniform drug exposure are achieved. improves the therapeutic effect.

CN118922183APending Publication Date: 2024-11-08IMMUNEERING CORPORATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380018552.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-06
Filing Date
2023-01-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing MEK inhibitors have problems with tolerance limitation, effect-like toxicity and acquired drug resistance in clinical applications, and the long half-life leads to uneven drug exposure, affecting the therapeutic effect.

Method used

A new class of dual MEK inhibitors has short in vivo half-life and cyclic activity inhibitory properties, and reduce metabolic stability through specific chemical structure designs, such as changes in halogen atoms at the R3 position, and achieve short BID administration. Effective effect.

Benefits of technology

Deep circulating inhibition of the MAPK pathway over the 12-24-hour cycle is achieved, maximizing drug exposure, reducing drug valley value, and improving treatment tolerance and effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922183A_ABST
    Figure CN118922183A_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing, and preparing compounds represented by the general formula (III), including pharmaceutically acceptable salts thereof, or synthetic intermediates thereof: # imgabs0 which act as MEK inhibitors and are capable of exhibiting one or more beneficial therapeutic effects, including the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of chemistry and medicine. More specifically, the present invention relates to MEK inhibitors, MEK immuno-oncology inhibitors, technologies for designing and synthesizing such MEK inhibitors, MEK immuno-oncology compositions comprising MEK inhibitors and MEK immuno-oncology inhibitors, and methods for treating diseases comprising administering MEK inhibitors. Background Art

[0002] In healthy cells, the mitogen-activated protein kinase (MAPK) pathway utilizes parallel signaling streams to decipher complex extracellular stimuli and drive cellular programs that promote proliferation, differentiation, survival, motility, apoptosis, and stress responses. The RAS-RAF-MEK-ERK cascade is one of three distinct MAPK pathways and the one most frequently exploited in cancer. Gain-of-function mutations in RAS (KRAS, NRAS, HRAS) or RAF (ARAF, BRAF, CRAF / RAF1) are common in cancer. RAS mutations alone account for up to 95% of pancreatic cancers (KRAS), 20%-30% of melanomas (NRAS), 40% of non-small cell lung cancers (KRAS), and 45% of colorectal cancers (KRAS). Patients with these tumor types often face poor prognoses and limited treatment options, leading to intensive research into how to develop active drugs targeting this pathway. As a central node in the MAPK signaling pathway, MEK has been an attractive drug target for over two decades, but in the clinic, MEK inhibitors are plagued by class-effect toxicity and acquired resistance. Furthermore, regulatory approval has been largely limited to RAF-mutant disease. Clinical setbacks in the RAS-mutant setting may stem from a mechanistic blind spot of first-generation MEK inhibitors, which leads to increased pathway reactivation, which in turn requires sustained target engagement, limiting drug tolerability. Therefore, new approaches targeting MEK with greater tolerability and broader activity are urgently needed.

[0003] MEK1 and MEK2 (MEK) are closely related dual-specificity kinases that are activated by upstream mediators including RAF (ARAF, BRAF, RAF1 [also known as CRAF]), KSR (KSR1, KSR2), and RAS (KRAS, NRAS, HRAS). When activated by phosphorylation on two serine residues, pMEK in turn promotes phosphorylation of ERK1 and ERK2 (pERK), leading to the regulation of multiple downstream targets. Inappropriate activation of this pathway has been associated with a variety of oncogenic processes including proliferation, survival, growth, tumor metabolism, migration, and immune evasion. Multiple targeted agents have been and continue to be developed with the goal of reducing MAPK pathway activity at various levels from RAS to ERK, and several agents in this field have achieved clinical proof of concept, including targeting KRAS. G12C BRAF V600E / K Common challenges faced by drugs that block this core homeostatic pathway include clinically limiting toxicities from sustained targeted inhibition, and the potential for toxicity based on the presence of specific target mutations (e.g., KRAS G12C BRAF V600E / K ) of patients with tumours that are treatable, and acquired or adaptive drug resistance that limits the clinical utility of emerging drugs.

[0004] Previous MEK inhibitors suffered from one or more key deficiencies. First-generation MEK inhibitors counteracted pathway reactivation by maintaining drug occupancy in the MEK allosteric pocket throughout the dosing cycle (i.e., chronic inhibition). This was typically achieved by either conferring a long half-life on the drug and dosing it regularly or by creating drugs with intermediate half-lives and dosing them more frequently. Both approaches result in chronic inhibition of the MAPK pathway by maintaining a steady-state trough level of active drug. Second-generation MEK inhibitors counteract pathway reactivation by engaging the allosteric pocket in MEK in a unique manner that prevents RAF activation of MEK itself, yet still possesses a long half-life, resulting in chronic pathway ablation. This continued disruption of the core biological pathway presents at least three well-documented challenges for first- and second-generation MEK inhibitors: (1) tolerability: clinically limiting, class-effect safety concerns (Heinzerling 2019), (2) acquired / adaptive resistance: selective pressure for escape mutations (Corcoran 2011), and (3) clinical utility: reduced drug-drug combination potential due to limitations in drug-related safety and toxicity profiles. Consequently, first-generation MEK inhibitors suffer from multiple drawbacks: (1) persistent target occupancy driving acquired and / or adaptive resistance and dose-limiting toxicities, (2) mechanistic drug-target interactions that fail to effectively control pathway reactivation (e.g., CRAF bypass), and (3) limited clinical utility of drug combinations due to high baseline drug-related toxicities.

[0005] The common feature of almost all MEK inhibitors is their allosteric target involvement, which is highly selective for MEK and not ATP competitive, and is generally referred to as type III allosteric inhibitors. The first generation of MEK inhibitors, such as trametinib, cobimetinib, bemetinib and selumetinib, continuously inhibit MAPK pathway activity by occupying MEK1 and MEK2 for a long time. However, they exhibit dose-limiting class effect toxicity and are sensitive to pathway reactivation events. The second generation of MEK inhibitors, such as VS-6766 (CH5126766, with an average terminal half-life of 53.6 hours, Guo et al. Lancet Oncol. 2020 November; 21(11): 1478-1488), exhibits mechanistic resistance to pathway reactivation. They also continuously inhibit MAPK pathway activity by occupying MEK1 and MEK2 for a long time, and therefore have class effect toxicity similar to that of the first generation inhibitors. Table 1 is a summary of some characteristics of MEK inhibitors used for the treatment of RAS mutation diseases.

[0006] Table 1 Characteristics of MEK inhibitors of different generations in RAS mutation diseases

[0007]

[0008] Thus, there remains an unmet need for improved MEK inhibitor compounds, such as MEK inhibitor compounds with shorter half-lives as measured in mouse and / or human liver microsomal stability assays. Summary of the Invention

[0009] The compounds disclosed in this application have been found to exhibit surprising and unexpected biological effects.In some embodiments, the compounds of this application are useful as dual MEK inhibitors that exhibit surprising and unexpected biological effects.

[0010] In some embodiments, the compound is a MEK inhibitor compound characterized by an unexpectedly short in vivo half-life, including a novel dual MEK inhibitor with an unprecedented short half-life that can be used to cyclically inhibit and release MEK and ERK activity. Unlike previous MEK inhibitors, applicants have discovered compounds that can be used in therapeutic methods designed to maximize drug exposure at Cmax while achieving a near-zero drug trough over a 12- to 24-hour period. In some embodiments, the compounds disclosed herein can be administered on a schedule to drive deep cyclic inhibition of the MAPK pathway in a subject.

[0011] Some embodiments relate to compounds having the chemical structure of formula (IV)

[0012]

[0013] or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, fluorine or chlorine, R 13 Ethyl or -NR A R B , where R A is hydrogen and R B is methyl, Z2 is -NR 5 R 5’ 、 R 5 is a C1 to C6 alkyl group, and R 5 ' is a C1 to C6 alkyl group. In some embodiments, R 5 In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, Z2 is -NR 5 R 5’ In some embodiments, R 13 -NR A R B In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Or, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, R 13 In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, Z2 is In some embodiments, R 13 In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, R 13 -NR A R B In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, Z2 is In some embodiments, R 13 In some embodiments, R 13 -NR A R B In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is or a pharmaceutically acceptable salt thereof.

[0014] Some embodiments relate to a compound having the structure of Formula (III):

[0015]

[0016] Including pharmaceutically acceptable salts thereof, wherein R 2 L; R 6 Selected from the group consisting of H or fluorine, chlorine or bromine; R 7 H; R 13 and optionally substituted amine, C1 to C6 alkyl, H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl and L; R 3 is chlorine, X is –O–, and Y is L is –Z1-Z2, Z1 is –CH2–; and Z2 is selected from the group consisting of: –NR 5 R 5′, optionally substituted C3 to C8 heterocyclyl, –CH2–, –O–, –S–, S═O, –SO2–, C═O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 Aryl, optionally substituted C3 to C 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and each R 5 and R 5′ In some embodiments, Z2 is -NR 5 R 5′ In some embodiments, R 5 In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, Z2 is In some embodiments, Z2 is optionally substituted wherein n is 1, 2, 3, or 4. In some embodiments, n is 1. In some embodiments, R 13 -NR A R B , where R A and R B Each independently selected from hydrogen or C 1-6 In some embodiments, R A is hydrogen and R B In some embodiments, R 13 is a C1 to C6 alkyl group. In some embodiments, R 13 In some embodiments, R 6 In some embodiments, R 6 In some embodiments, R 6 For H.

[0017] Some embodiments relate to a compound having the structure of Formula (III):

[0018]

[0019] Including pharmaceutically acceptable salts thereof, wherein R 2 L; R 6 Selected from the group consisting of H or fluorine, chlorine or bromine; R 7 H; R 13 is a C1 to C6 alkyl group; R 3 is chlorine; X is –O–; Y is L is –Z1-Z2; Z1 is –CH2–; Z2 is –NR 5 R 5′ ; and each R 5 and R 5′ Independently selected from optionally substituted C1 to C6 alkyl.

[0020] Some embodiments relate to a compound having the structure of Formula (III):

[0021]

[0022] Including pharmaceutically acceptable salts thereof, wherein R 2and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl and L, R 6 and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl and L; R 7 and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene,10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl and L; R 13 and optionally substituted C1 to C6 alkyl, optionally substituted amino, H, deuterium, hydroxy, halogen, cyano, nitro, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl and L; R 3 is chlorine, bromine or iodine; X is –O–, C(R 5 )2、CH(R 5 ), CH2, Y is C(R 5 )2、CH(R 5 ), CH2, –O–, L is –Z1-Z2 or –Z1-Z2-Z3; Z1 is selected from the group consisting of –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); Z2 is selected from the group consisting of: –NR 5 R 5′ , –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5, –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); Z3 is selected from the group consisting of –CH2–, –O–, –S–, S═O, –SO2–, C═O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5-, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and each R 5 and R 5′ independently selected from optionally substituted C1 to C6 alkyl, H, deuterium, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group and optionally substituted C3 to C 10 Heteroaryl.

[0023] In some embodiments, the design of certain compounds is based in part on the applicant's discovery that in R 3 A specific halogen atom change from fluorine (F) to chlorine (Cl) at position 1 is a key site substitution that unexpectedly contributes to further decrease metabolic stability when exposed to mouse or human microsomes. 3 This change from F to Cl is not obvious, as exemplified by a key example within the same target drug class of MEK inhibitors. Bemetinib and selumetinib are US FDA-registered MEK inhibitors that differ by a single halogen, where the F- in bemetinib is changed to Cl in selumetinib. Selumetinib (at ≥6.2 hours – National Center for Biotechnology Information (2023). CID 10127622 PubChem compound abstract for selumetinib. Retrieved on January 5, 2023, from https: / / pubchem.ncbi.nlm.nih.gov / compound / Selumetinib) showed a human plasma drug half-life that was approximately twice that of binimetinib (at 3.5 hours – National Center for Biotechnology Information (2023). CID 10288191 PubChem compound abstract for binimetinib. Retrieved on January 5, 2023, from https: / / pubchem.ncbi.nlm.nih.gov / compound / Binimetinib). 3 Among the newly synthesized analogs of Formula (III) with Cl, many drug-like properties varied unpredictably, but we consistently observed low microsomal metabolic stability, which is a critical and desirable attribute for designing short-acting, dual MEK inhibitors to achieve BID dosing.

[0024] Some embodiments relate to a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable salt thereof. Some embodiments relate to a method of treating cancer. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a compound as described herein or a pharmaceutical composition thereof. Some embodiments relate to the use of a compound as described herein for treating cancer. Some embodiments relate to a compound selected from the group consisting of: 4-((dimethylamino)methyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (Compound 244); 4-((dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yldimethylcarbamate In some embodiments, the compound is 4-((dimethylamino)methyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 244). In some embodiments, the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methyl-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 253). In some embodiments, the compound is 4-((dimethylamino)methyl)-3-(3-(ethylsulfonamido)-2-fluorobenzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 269).

[0025] Some embodiments relate to compounds selected from the group consisting of: 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (Compound 245); 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 246); 6-chloro-3-(2-fluoro-3-((2, 2-(2,2-trifluoroethyl)sulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 247); 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (Compound 249); 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate -yl dimethylcarbamate (Compound 254); 3-(2-chloro-3-(ethylsulfonamido)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 255); 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 256); 6-chloro-3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 257); )-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 257); 3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 258); and 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 274). In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 245). In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate (Compound 246).In some embodiments, the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (Compound 249). In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 254). In some embodiments, the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 245). In some embodiments, the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 256). In some embodiments, the compound is 6-chloro-3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate (Compound 257). In some embodiments, the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate. In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (Compound 274).

[0026] Some embodiments relate to a compound selected from the group consisting of: 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yldimethylcarbamate; 3-(2-chloro-3-(ethylsulfamoyl)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yldimethylcarbamate; 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yldimethylcarbamate; 4-(azetidin-1-ylmethyl)-3-(2-chloro-3-((N- dimethylcarbamate; 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; and 4-(azetidin-1-ylmethyl)-6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate. In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 3-(2-chloro-3-(ethylsulfamoyl)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 4-(azetidin-1-ylmethyl)-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-2H-chromen-7-yldimethylcarbamate. In some embodiments, the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate.In some embodiments, the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0027] Some embodiments relate to a compound selected from the group consisting of: 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 3-(3-(ethylsulfonamido)-2-fluorobenzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 3-(2-Fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-((methyl(prop-2-yn-1-yl)amino)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; (((CyanomethyI)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 4-((dimethylamino)methyl)-3-(2-fluoro-3-(methyl(sulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate; 4-((dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl) In some embodiments, the compound is 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 3-(3-(ethylsulfonamido)-2-fluorobenzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-((methyl(prop-2-yn-1-yl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.In some embodiments, the compound is 4-(((cyanomethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-(methyl(sulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. In some embodiments, the compound is 3-(3-((tert-butylsulfinyl)amino)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The pharmacokinetics of exemplary compounds of the disclosure compared to similar compounds are presented.

[0029] Figure 2A A graph showing pERK:total ERK (activated) in the A549 lung cancer model is shown; Figure 2B A graph showing pERK:total ERK (activated) in the A375 model is shown; Figure 2C Shown is a graph of pERK:total ERK in the SK-MEL-2 melanoma model.

[0030] Figure 3 Figures showing studies of the Colon-26 syngeneic CRC tumor mouse model (BID) are shown.

[0031] Figure 4 Figures showing studies of the Colon-26 syngeneic CRC tumor mouse model (QD) are shown.

[0032] Figure 5 A table showing compounds of the present disclosure is presented. DETAILED DESCRIPTION

[0033] In some embodiments, MEK inhibitors are provided. Various embodiments of these compounds include compounds having the structure of Formula I as described herein or pharmaceutically acceptable salts thereof. In some embodiments, prodrugs, metabolites, stereoisomers, hydrates, solvates, polymorphs, and pharmaceutically acceptable salts of the compounds disclosed herein are provided.

[0034] In certain aspects, provided herein are methods or uses for treating, preventing, or ameliorating a disease or condition in a subject, comprising administering to the subject at least one compound disclosed herein. In some embodiments, provided are methods or uses for treating, preventing, or ameliorating cancer, comprising administering a compound having a structure of Formula (I), (Ia), (Ib), (Ic), (Id) (II), (IIa), (IIb), (IIc), (IId), (III) or (IV), as described herein. In some embodiments, provided are methods or uses for treating cancer cachexia, comprising administering a compound having a structure of Formula (I), (Ia), (Ib), (Ic), (Id) (II), (IIa), (IIb), (IIc), (IId), (III) or (IV), as described herein.

[0035] definition

[0036] Unless otherwise defined, the technical and / or scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. Where multiple definitions exist for a term in this article, those in this section shall prevail unless otherwise stated. The singular forms "a / an" and "said" used in the specification and the appended claims include plural indicators unless the context clearly indicates otherwise. Unless otherwise stated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, and pharmacology are employed. Unless otherwise stated, the conjunction "or" or "and" is used to mean "and / or". In addition, the use of the term "including" and other forms such as "include," "includes," and "included" is not restrictive. As used in this specification, whether in a transitional phrase or in the body of the claim, the term "comprise(s)" and "comprising" should be interpreted as having an open meaning. That is, these terms should be interpreted synonymously with the phrase "at least having" or "at least including." When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.

[0037] Although the present disclosure has been shown and described in detail in the foregoing description, such description should be considered illustrative or exemplary rather than restrictive. The present disclosure is not limited to the disclosed embodiments. Variations of the disclosed embodiments can be understood and implemented by those skilled in the art in practicing the claimed disclosure by studying this disclosure and the appended claims.

[0038] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art can translate from the plural to the singular and / or from the singular to the plural as is appropriate to the context and / or application. For the sake of clarity, various singular / plural permutations may be explicitly set forth herein. The indefinite article "a" or "an" does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.

[0039] All references cited herein are hereby incorporated by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.

[0040] Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meanings to those skilled in the art and are not to be limited to special or customized meanings unless expressly so defined herein. It should be noted that when describing certain features or aspects of the present disclosure, the use of a particular term should not be construed as implying that the term is to be redefined herein to include any particular feature of the feature or aspect of the disclosure with which the term is associated.

[0041] Where a range of values ​​is provided, it is understood that the upper and lower limits, and every intervening value between the upper and lower limits of that range, are encompassed within the embodiments.

[0042] As used herein, the term "prodrug" refers to a medicament that is converted into a parent drug in vivo. Prodrugs are generally useful because, in some cases, they may be easier to use than the parent drug. For example, they can be bioavailable by oral administration, while the parent is not. Prodrugs can also have improved solubility exceeding the parent drug in pharmaceutical compositions. A non-limiting example of a prodrug is a compound used as an ester ("prodrug") to promote transmission through the cell membrane, where water solubility is harmful to mobility, but once water solubility is beneficial in the cell, the compound is metabolically hydrolyzed into carboxylic acid, i.e., an active entity. Another example of a prodrug can be a short peptide (polyamino acid) combined with an acid group, in which peptides are metabolized to display an active moiety. Conventional methods for selecting and preparing suitable prodrug derivatives are described in, for example, Design of Prodrugs (H. Bundgaard, ed., Elsevier, 1985), which is incorporated herein by reference in its entirety.

[0043] Metabolites of the compounds disclosed herein include active species produced upon introduction of the compounds into a biological milieu.

[0044] Compounds disclosed herein have at least one chiral center, they can exist as racemates or as each enantiomer, and can exist as enantiomer-enriched mixtures of enantiomers. It should be noted that all of these isomers and mixtures thereof are included within the scope of the present invention. In addition, the crystalline form of compounds disclosed herein can exist as alternative polymorphs. Such polymorphs are included in one embodiment of the present invention. In addition, some compounds of the present invention can form solvates with water (i.e., hydrates) or common organic solvents. Such solvates are included in one embodiment of the present invention.

[0045] As used herein, "pharmaceutically acceptable salt" refers to a salt of a compound that does not significantly stimulate the organism to which it is administered and does not eliminate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutically acceptable salts can be obtained by reacting the compound with an inorganic acid such as a hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid, phosphoric acid, etc. Pharmaceutically acceptable salts can also be obtained by reacting the compound with an organic acid such as an aliphatic or aromatic carboxylic acid or sulfonic acid, for example, acetic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, or naphthalenesulfonic acid. Pharmaceutically acceptable salts can also be obtained by reacting the compound with a base to form a salt (such as an ammonium salt, an alkali metal salt such as a sodium salt or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt), an organic base such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, a C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and a salt with an amino acid such as arginine, lysine, etc.

[0046] If the manufacture of a pharmaceutical formulation involves the intimate mixing of a pharmaceutical excipient and the active ingredient in its salt form, it may be necessary to use a non-basic pharmaceutical excipient, ie, an acidic or neutral excipient.

[0047] In various embodiments, the compounds disclosed herein can be used alone, in combination with other compounds disclosed herein, or in combination with one or more other agents active in the therapeutic areas described herein.

[0048] The term "halogen atom" as used herein means any of the radioactive stable atoms of column 7 of the periodic table, such as fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.

[0049] As used herein, the term "ester" refers to a ester having the formula -(R) n The chemical moiety -COOR', wherein R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon), and wherein n is 0 or 1.

[0050] As used herein, the term "amide" refers to a compound having the formula -(R) n -C(O)NHR' or -(R) n -NHC(O)R', wherein R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon), wherein n is 0 or 1. Amides can be amino acids or peptide molecules attached to the molecules of the present invention, thereby forming a prodrug.

[0051] Any amine, hydroxyl, or carboxyl side chain on the compounds disclosed herein can be esterified or amidated. The procedures and specific groups used to achieve this are known to those skilled in the art and can be readily found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.

[0052] As used herein, the term "aromatic" refers to an aromatic group having at least one ring with a conjugated π electron system, and includes carbocyclic aromatic groups (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic or condensed ring polycyclic (i.e., rings sharing adjacent carbon atom pairs) groups. The term "carbocycle" refers to a compound containing one or more covalently closed ring structures and the atoms of the main chain forming the ring are all carbon atoms. Therefore, the term distinguishes carbocycle from a heterocycle in which the main chain of the ring contains at least one atom different from carbon. The term "heteroaromatic" refers to an aromatic group containing at least one heterocycle.

[0053] As used herein, “C a to C b ”, where “a” and “b” are integers referring to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, aryl, heteroaryl, or heterocyclyl group. That is, the ring of an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group can contain from “a” to “b” (inclusive) carbon atoms. Thus, for example, a “C1 to C4 alkyl” group or a “C1-C4 alkyl” group refers to all alkyl groups having from 1 to 4 carbon atoms, i.e. CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2-, CH3CH2CH(CH3)-, and (CH3)3C-. Similarly, for example, a cycloalkyl group can contain all atoms from "a" to "b" (inclusive) in the ring, such as a C3-C8 cycloalkyl group, 3 to 8 carbon atoms. If "a" and "b" are not specified for an alkyl, cycloalkyl, or cycloalkenyl group, it is assumed that the atoms described in these definitions are all carbon atoms. The broadest range. Similarly, a "4- to 7-membered heterocyclyl" group refers to all heterocyclyl groups having a total of 4 to 7 ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by either of the foregoing two numbers. For example, C1-C6 alkyl includes C1, C2, C3, C4, C5, and C6 alkyl, C2 C-C6 alkyl, C1-C3 alkyl, etc. Similarly, C3-C8 carbocyclyl or cycloalkyl each include hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms, or a range defined by either of the two numbers, such as C3-C7 cycloalkyl or C5-C6 cycloalkyl. As another example, 3 to 10 membered heterocyclyl includes 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms, or a range defined by either of the two numbers, such as 4 to 6 or 5 to 7 membered heterocyclyl.

[0054] As used herein, "alkyl" refers to a fully saturated (no double or triple bond) hydrocarbon group of a straight or branched hydrocarbon chain. An alkyl group can have 1 to 20 carbon atoms (whenever it occurs in this article, a numerical range such as "1 to 20" refers to each integer in a given range; for example, "1 to 20 carbon atoms" means that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although this definition also encompasses the occurrence of the term "alkyl" in which no numerical range is specified). The alkyl group can also be a medium-sized alkyl group with 1 to 10 carbon atoms. The alkyl group can also be a low-alkyl group with 1 to 5 carbon atoms. The alkyl group of a compound can be designated as "C1-C4 alkyl" or similar names. For example only, "C1-C4 alkyl" means that there are one to four carbon atoms in the alkyl chain, that is, the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, and the like.

[0055] The alkyl group may be substituted or unsubstituted. When substituted, the substituent is one or more groups individually and independently selected from the group consisting of alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, thiol, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thioamino Optionally substituted amino groups include formyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamido, N-sulfonamido, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and protected derivatives thereof. When a substituent is described as "optionally substituted," the substituent may be substituted by one of the substituents described above.

[0056] As used herein, "alkenyl" refers to an alkyl group containing one or more double bonds in a straight or branched hydrocarbon chain. An alkenyl group may be unsubstituted or substituted. When substituted, the substituents may be selected from the same groups disclosed above for substitution of alkyl groups. An alkenyl group may have from 2 to 20 carbon atoms, although this definition also encompasses occurrences of the term "alkenyl" where no numerical range is specified. An alkenyl group may also be a medium-sized alkenyl group having from 2 to 9 carbon atoms. An alkenyl group may also be a lower alkenyl group having from 2 to 4 carbon atoms. An alkenyl group of a compound may be designated as "C 2-4"C-alkenyl" or similar names. For example only, "C 2-4 The term "alkenyl" refers to an alkenyl group having two to four carbon atoms, i.e., an alkenyl chain selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl, and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0057] As used herein, "alkynyl" refers to an alkyl group containing one or more triple bonds in a straight or branched hydrocarbon chain. An alkynyl group may be unsubstituted or substituted. When substituted, the substituents may be selected from the same groups disclosed above for substitution of alkyl groups. An alkynyl group may have from 2 to 20 carbon atoms, although this definition also encompasses occurrences of the term "alkynyl" where no numerical range is specified. An alkynyl group may also be a medium-sized alkynyl group having from 2 to 9 carbon atoms. An alkynyl group may also be a lower alkynyl group having from 2 to 4 carbon atoms. An alkynyl group of a compound may be designated as "C 2-4 Alkynyl" or similar names. For example only, "C 2-4 "Alkynyl" means that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.

[0058] As used herein, "heteroalkyl" refers to a straight or branched hydrocarbon chain containing one or more heteroatoms in the backbone, i.e., elements other than carbon, including, but not limited to, nitrogen, oxygen, and sulfur. A heteroalkyl group may have from 1 to 20 carbon atoms, although this definition also encompasses occurrences of the term "heteroalkyl" where no numerical range is specified. A heteroalkyl group may also be a medium-sized heteroalkyl group having from 1 to 9 carbon atoms. A heteroalkyl group may also be a lower heteroalkyl group having from 1 to 4 carbon atoms. A heteroalkyl group of a compound may be designated as "C 1-4 Heteroalkyl" or similar designations. A heteroalkyl group may contain one or more heteroatoms. For example only, "C 1-4 "Heteroalkyl" means that there are one to four carbon atoms in the heteroalkyl chain and additionally one or more heteroatoms are present in the backbone of the chain.

[0059] As used herein, "aryl" refers to a carbocyclic ring (all carbon) or two or more fused rings (rings that share two adjacent carbon atoms) with a completely delocalized π electron system. Examples of aryl groups include, but are not limited to, benzene, naphthalene, and azulene. Aryl groups can be substituted or unsubstituted. When substituted, the hydrogen atoms are replaced by substituents, which are one or more groups independently selected from the following: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, sulfhydryl, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamido, N-sulfonamido, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfo, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono-substituted and di-substituted amino, and protected derivatives thereof. When substituted, the substituents on the aryl group may form a non-aromatic ring fused to the aryl group, including cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl.

[0060] As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic ring system (a ring system with a completely delocalized π electron system), one or two or more fused rings, containing one or more heteroatoms, i.e., elements other than carbon, including but not limited to nitrogen, oxygen, and sulfur. Examples of heteroaryl rings include but are not limited to furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and triazine. Heteroaryl groups can be substituted or unsubstituted. When substituted, the hydrogen atom is replaced by a substituent, which is one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, thiol, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamido, N-sulfonamido, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, thio, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido and amino, including mono-substituted and di-substituted amino, and protected derivatives thereof. When substituted, the substituents on the heteroaryl group may form a non-aromatic ring fused to the aryl group, including cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl.

[0061] As used herein, "aralkyl" or "arylalkyl" refers to an aryl group attached as a substituent through an alkylene group. The alkylene and aryl groups of the aralkyl group can be substituted or unsubstituted. Examples include, but are not limited to, benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group.

[0062] As used herein, "heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group attached as a substituent via an alkylene group. The alkylene and heteroaryl groups of the heteroaralkyl group can be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furanylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, as well as substituted and benzo-fused analogs thereof. In some cases, the alkylene group is a lower alkylene group.

[0063] As used herein, "alkylene" refers to a branched or straight chain fully saturated diradical chemical group containing only carbon and hydrogen, which is connected to the rest of the molecule via two points of attachment (i.e., alkanediyl). An alkylene group can have from 1 to 20 carbon atoms, although this definition also encompasses occurrences of the term alkylene where no numerical range is specified. An alkylene group can also be a medium-sized alkylene group having from 1 to 9 carbon atoms. An alkylene group can also be a lower alkylene group having from 1 to 4 carbon atoms. An alkylene group can be designated as "C 1-4 Alkylene" or similar names. For example only, "C 1-4 “Alkylene” means that there are one to four carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of methylene, ethylene, ethane-1,1-diyl, ethylene, propane-1,1-diyl, propane-2,2-diyl, 1-methyl-ethylene, butene, butane-1,1-diyl, butane-2,2-diyl, 2-methyl-propane-1,1-diyl, 1-methyl-propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, 1,2-dimethyl-ethylene, and 1-ethyl-ethylene.

[0064] As used herein, "alkenylene" refers to a straight or branched chain diradical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, which is connected to the rest of the molecule via two points of attachment. An alkenylene group can have from 2 to 20 carbon atoms, although this definition also encompasses occurrences of the term alkenylene where no numerical range is specified. An alkenylene group can also be a medium-sized alkenylene group having from 2 to 9 carbon atoms. An alkenylene group can also be a lower alkenylene group having from 2 to 4 carbon atoms. An alkenylene group can be designated as "C 2-4 Alkenylene" or similar names. For example only, "C 2-4The term "alkenylene" means that there are two to four carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of vinylene, ethylene-1,1-diyl, propenylene, propen-1,1-diyl, prop-2-ene-1,1-diyl, 1-methylvinylene, but-1-enyl, but-2-enyl, buta-1,3-dienyl, butene-1,1-diyl, buta-1,3-diene-1,1-diyl, buta-2-enyl, buta-1,3-dienyl, buta-1,1-diyl, buta-2-enyl, buta-1,3-diene ... -ene-1,1-diyl, but-3-ene-1,1-diyl, 1-methyl-prop-2-ene-1,1-diyl, 2-methyl-prop-2-ene-1,1-diyl, 1-ethyl-vinylene, 1,2-dimethyl-vinylene, 1-methyl-propenylene, 2-methyl-propenylene, 3-methyl-propenylene, 2-methyl-propenylene-1,1-diyl and 2,2-dimethyl-ethylene-1,1-diyl.

[0065] As used herein, "alkylene" refers to a divalent group, such as =CR'R", which is attached to one carbon of another group to form a double bond. Alkylene groups include, but are not limited to, methylene (=CH2) and ethylene (=CHCH3). As used herein, "arylalkylene" refers to an alkylene group in which R' and R" are aryl groups. Alkylene groups can be substituted or unsubstituted.

[0066] As used herein, "alkoxy" refers to the formula -OR, where R is an alkyl group as defined above, for example, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, tert-pentoxy, etc. The alkoxy group can be substituted or unsubstituted.

[0067] As used herein, "alkylthio" refers to a radical of the formula -SR, wherein R is an alkyl radical as defined above, for example, methylthio, ethylthio, n-propylthio, 1-methylethylthio (isopropylthio), n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, etc. Alkylthio groups can be substituted or unsubstituted.

[0068] As used herein, "aryloxy" and "arylthio" refer to RO- and RS-, respectively, where R is an aryl group, such as, but not limited to, phenyl. Both aryloxy and arylthio groups can be substituted or unsubstituted.

[0069] As used herein, "acyl" refers to -C(=O)R, wherein R is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl are as defined herein. Non-limiting examples include formyl, acetyl, propionyl, benzoyl and acryloyl.

[0070] As used herein, "cycloalkyl" refers to a fully saturated (no double bonds) monocyclic or polycyclic hydrocarbon ring system. When composed of two or more rings, these rings can be joined together in a fused, bridged or spiro-connected manner. Cycloalkyl can be C3 to C 10 In some embodiments, the cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. If substituted, unless otherwise indicated, the substituents may be alkyl or selected from those indicated above for the substitution of alkyl groups. When substituted, the substituents on the cycloalkyl group may form an aromatic ring fused to the cycloalkyl, including aryl and heteroaryl groups.

[0071] As used herein, "cycloalkenyl" refers to a cycloalkyl group containing one or more double bonds in the ring, but if there are more than one double bond, they cannot form a completely delocalized π electron system in the ring (otherwise the group would be "aryl", as defined herein). When composed of two or more rings, the rings may be linked together in a fused, bridged, or spiro-connected manner. A cycloalkenyl group may be unsubstituted or substituted. When substituted, unless otherwise indicated, the substituents may be alkyl or selected from the groups disclosed above for alkyl substitution. When substituted, the substituents on the cycloalkenyl group may form an aromatic ring fused to the cycloalkenyl group, including aryl and heteroaryl.

[0072] As used herein, "cycloalkynyl" refers to a cycloalkyl group containing one or more triple bonds in the ring. When composed of two or more rings, the rings may be joined together in a fused, bridged, or spiro-connected manner. A cycloalkynyl group may be unsubstituted or substituted. When substituted, unless otherwise indicated, the substituents may be alkyl or selected from the groups disclosed above for alkyl substitution. When substituted, the substituents on the cycloalkynyl group may form an aromatic ring fused to the cycloalkynyl group, including aryl and heteroaryl groups.

[0073] As used herein, "heteroalicyclic" or "heteroalicyclic group" refers to a stable 3- to 18-membered ring consisting of carbon atoms and one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. "Heteroalicyclic" or "heteroalicyclic group" can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can be joined together in a fused, bridged, or spiro-connected manner; and the nitrogen, carbon, and sulfur atoms in "heteroalicyclic" or "heteroalicyclic group" can be optionally oxidized; nitrogen can be optionally quaternized; and the ring can also contain one or more double bonds, provided that they do not form a completely delocalized π-electron system in all rings. The heteroalicyclic group can be unsubstituted or substituted. When substituted, the substituents can be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, thiol, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and protected derivatives thereof. Examples of such "heteroalicyclic" or "heteroalicyclic groups" include, but are not limited to, azepanyl, acridinyl, carbazolyl, cinnolidinyl, dioxolanyl, imidazolinyl, morpholinyl, oxiranyl, piperidinyl N-oxide, piperidinyl, piperazinyl, pyrrolidinyl, 4-piperidonyl, pyrazolidinyl, 2-oxopyrrolidinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, and thiomorpholinyl sulfone. When substituted, the substituents on the heteroalicyclic group can form an aromatic ring fused to the heteroalicyclic group, including aryl and heteroaryl groups.

[0074] As used herein, the term "(cycloalkenyl)alkyl" refers to a cycloalkenyl group attached via an alkylene group as a substituent. The alkylene and cycloalkenyl groups of the (cycloalkenyl)alkyl group may be substituted or unsubstituted. In some cases, the alkylene group is a lower alkylene group.

[0075] As used herein, the term "(cycloalkynyl)alkyl" refers to a cycloalkynyl group attached as a substituent via an alkylene group. The alkylene and cycloalkynyl groups of the (cycloalkynyl)alkyl group may be substituted or unsubstituted. In some cases, the alkylene group is a lower alkylene group.

[0076] As used herein, the term "O-carboxy" refers to a "RC(=O)O-" group, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic)alkyl, as defined herein. The O-carboxy group can be substituted or unsubstituted.

[0077] As used herein, the term "C-carboxy" refers to a "-C(=O)R" group, where R may be the same as defined for O-carboxy. The C-carboxy group may be substituted or unsubstituted.

[0078] As used herein, the term "trihalomethanesulfonyl" refers to an "X3CSO2-" group, where X is a halogen.

[0079] As used herein, the term "cyano" refers to a "-CN" group.

[0080] As used herein, the term "cyanato" refers to a "-OCN" group.

[0081] As used herein, the term "isocyanato" refers to a "-NCO" group.

[0082] As used herein, the term "thiocyanato" refers to a "-SCN" group.

[0083] As used herein, the term "isothiocyanato" refers to a "-NCS" group.

[0084] As used herein, the term "sulfinyl" refers to a "-S(=O)-R" group, where R may be the same as defined for O-carboxyl. A sulfinyl group may be substituted or unsubstituted.

[0085] As used herein, the term "sulfonyl" refers to a "-SO2R" group, where R can be the same as defined for O-carboxyl. A sulfonyl group can be substituted or unsubstituted.

[0086] As used herein, the term "S-sulfonamido" refers to "-SO2NR A R B " group, wherein R A and R B The S-sulfonyl group may be the same as defined for the O-carboxyl group.

[0087] As used herein, the term "N-sulfonamido" refers to "-SO2N(R A )(R B )" group, wherein R, R A and R B The sulfonyl group may be the same as defined for the O-carboxyl group. The sulfonyl group may be substituted or unsubstituted.

[0088] As used herein, the term "trihalomethanesulfonamido" refers to a "X3CSO2N(R)-" group, where X is a halogen and R may be the same as defined for O-carboxyl. The trihalomethanesulfonamido group may be substituted or unsubstituted.

[0089] As used herein, the term "O-carbamoyl" refers to "-OC(=O)NR A R B " group, wherein R A and R B The O-carbamoyl group may be the same as defined above.

[0090] As used herein, the term "N-carbamoyl" refers to "ROC(=O)NR A -" group, where R and R A The same as defined for the O-carboxyl group. The N-carbamoyl group may be substituted or unsubstituted.

[0091] As used herein, the term "O-thiocarbamoyl" refers to "-OC(=S)-NR A R B " group, wherein R A and R B The O-thiocarbamoyl group may be substituted or unsubstituted.

[0092] As used herein, the term "N-thiocarbamoyl" refers to "ROC(=S)NR A -" group, where R and R A The same as defined for the O-carboxyl group. The N-thiocarbamoyl group may be substituted or unsubstituted.

[0093] As used herein, the term "C-amido" refers to "-C(=O)NR A R B " group, wherein R A and R B The C-amide group may be substituted or unsubstituted.

[0094] As used herein, the term "N-amido" refers to "RC(=O)NR A -" group, where R and R A The N-amide group may be substituted or unsubstituted.

[0095] As used herein, the term "amino" refers to "-NRA R B " group, wherein R A and R B are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl are as defined herein.

[0096] As used herein, the term "aminoalkyl" refers to an amino group attached through an alkylene group.

[0097] As used herein, the term "ester" refers to a "-C(=O)OR" group, where R may be the same as defined for an O-carboxyl group. Esters may be substituted or unsubstituted.

[0098] As used herein, the term "lower aminoalkyl" refers to an amino group connected through a lower alkylene group. The lower aminoalkyl group can be substituted or unsubstituted.

[0099] As used herein, the term "lower alkoxyalkyl" refers to an alkoxy group connected through a lower alkylene group. The lower alkoxyalkyl group may be substituted or unsubstituted.

[0100] As used herein, the term "acetyl" refers to a -C(=O)CH3 group.

[0101] As used herein, the term "trihalomethanesulfonyl" refers to a X3CS(=O)2- group, where X is a halogen.

[0102] As used herein, the term "O-carbamoyl" refers to -OC(=O)-NR, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic)alkyl, as defined herein. The O-carbamoyl group can be substituted or unsubstituted.

[0103] As used herein, the term "N-carbamoyl" refers to a ROC(=O)NH- group, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic)alkyl, as defined herein. The N-carbamoyl group can be substituted or unsubstituted.

[0104] As used herein, the term "O-thiocarbamoyl" refers to -OC(=S)-NR, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic)alkyl, as defined herein. The O-thiocarbamoyl group can be substituted or unsubstituted.

[0105] As used herein, the term "N-thiocarbamoyl" refers to a ROC(=S)NH- group, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, or (heteroalicyclic)alkyl, as defined herein. The N-thiocarbamoyl group can be substituted or unsubstituted.

[0106] As used herein, the term "perhaloalkyl" refers to an alkyl group in which all hydrogen atoms are replaced by halogen atoms.

[0107] As used herein, the term "halogen" or "halo" refers to any of the radiostable atoms of column 7 of the periodic table, for example, fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.

[0108] As used herein, the term "carbocyclyl" refers to a non-aromatic cyclic ring or ring system containing only carbon atoms in the main chain of the ring system. When a carbocyclyl is a ring system, two or more rings can be joined together in a fused, bridged or spiro-connected manner. A carbocyclyl can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Thus, carbocyclyl includes cycloalkyl, cycloalkenyl and cycloalkynyl. A carbocyclyl group can have 3 to 20 carbon atoms, although this definition also encompasses occurrences of the term "carbocyclyl" in which no numerical range is specified. A carbocyclyl group can also be a medium-sized carbocyclyl group having 3 to 10 carbon atoms. A carbocyclyl group can also be a carbocyclyl group having 3 to 6 carbon atoms. A carbocyclyl group can be designated as "C 3-6 Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octyl, adamantyl, and spiro[4.4]nonyl.

[0109] As used herein, the term "(cycloalkyl)alkyl" refers to a cycloalkyl group attached as a substituent via an alkylene group. The alkylene and cycloalkyl groups of the (cycloalkyl)alkyl group may be substituted or unsubstituted. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like. In some cases, the alkylene group is a lower alkylene group.

[0110] As used herein, the term "cycloalkyl" refers to a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0111] As used herein, the term "cycloalkenyl" means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl.

[0112] As used herein, the term "heterocyclyl" refers to three-, four-, five-, six-, seven-, and eight- or more-membered rings in which carbon atoms, together with one to three heteroatoms, constitute the ring. However, the heterocyclyl group may optionally contain one or more unsaturated bonds positioned so as not to create an aromatic π-electron system. The heteroatoms are independently selected from oxygen, sulfur, and nitrogen.

[0113] The heterocyclic group may further contain one or more carbonyl or thiocarbonyl functional groups, thereby including within the definition both oxo and thio systems, such as lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, and the like.

[0114] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclyl group can be joined together in a fused, bridged or spiro-connected manner. The heterocyclyl group can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Heteroatoms can be present in non-aromatic or aromatic rings in the ring system. The heterocyclyl group can have 3 to 20 ring members (i.e., the number of atoms constituting the ring backbone, including carbon atoms and heteroatoms), although this definition also encompasses the occurrence of the term "heterocyclyl" in which no numerical range is specified. The heterocyclyl group can also be a medium-sized heterocyclyl group with 3 to 10 ring members. The heterocyclyl group can also be a heterocyclyl group with 3 to 6 ring members. The heterocyclyl group can be designated as "3-6 membered heterocyclyl" or similar names. In preferred six-membered monocyclic heterocyclyls, the heteroatoms are selected from one to three of O, N, or S, and in preferred five-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two heteroatoms of O, N, or S. Examples of heterocyclyl rings include, but are not limited to, azepanyl, acridinyl, carbazolyl, cinnolidinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidinyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxepenyl, 1,3-dioxepenyl, 1,4-dioxepenyl, 1,4-dioxepenyl, 1,3-oxanyl, 1,4-oxadienyl, 1,4-oxanyl, 2H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dithiolanyl, 1,3-dithiolanyl, 1,3-dithiolanyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinone, thiazolinyl, tetrahydrothiazolyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiamorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl, and tetrahydroquinoline.

[0115] As used herein, the term "(heterocyclyl)alkyl" refers to a heterocyclyl group attached as a substituent via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.

[0116] As used herein, the terms "purified," "substantially purified," and "isolated" mean that the compounds disclosed herein are free from other, different compounds with which the compounds of the invention are normally associated in their native state, such that the compounds of the invention comprise at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75%, by weight of a given sample.

[0117] Substituted groups are based on or derived from an unsubstituted parent group in which there is an exchange of one or more hydrogen atoms with another atom or group. Unless otherwise stated, when a group is considered to be "substituted", it is substituted by one or more substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C3-C7-carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), substituted), 5-10 membered heterocyclyl (optionally substituted by halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5-10 membered heterocyclyl-C1-C6-alkyl (optionally substituted by halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted by halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted by halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (C1-C6) alkyl (optionally substituted by halo, C1-C6 C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy substituted), 5-10 membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5-10 membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halo, cyano, hydroxy, C1-C6 alkoxy, C1-C6 alkoxy (C1-C6) alkyl (i.e., alkyl, for example, -C1-C6)alkyl, nitro, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamide, N-sulfonamide, C-carboxyl, O-carboxyl, acyl, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, and oxo (=O). When a group is described as "optionally substituted," the group may be substituted with the substituents described above.

[0118] In some embodiments, the substituted groups are substituted with one or more substituents individually and independently selected from the group consisting of C1-C4 alkyl, amino, hydroxy, and halogen.

[0119] It should be understood that certain radical naming conventions may include either monoradicals or diradicals, depending on the context. For example, when a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a diradical. For example, a substituent identified as an alkyl group requiring two points of attachment includes a diradical, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other radical naming conventions clearly indicate that the radical is a diradical, such as "alkylene" or "alkenylene."

[0120] Unless otherwise indicated, when a substituent is referred to as being "optionally substituted," it is meant that the substituent is a group that may be substituted with one or more groups individually and independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and disubstituted amino groups, and protected derivatives thereof. Protecting groups that can form protected derivatives of the above-mentioned substituents are known to those skilled in the art and can be found in references such as Greene and Wuts, supra.

[0121] As used herein, the term "agent" or "test agent" includes any substance, molecule, element, compound, entity, or combination thereof. It includes, but is not limited to, for example, proteins, polypeptides, peptides or mimetics, small organic molecules, polysaccharides, polynucleotides, etc. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise indicated, the terms "agent," "substance," and "compound" are used interchangeably herein.

[0122] As used herein, the term "analog" refers to a molecule that is structurally similar to a reference molecule but has been modified in a targeted and controlled manner by replacing specific substituents of the reference molecule with alternative substituents. Analogs are expected by those skilled in the art to exhibit the same, similar, or improved utility compared to the reference molecule. The synthesis and screening of analogs to identify variants of known compounds with improved properties (such as higher binding affinity for the target molecule) is a well-known method in medicinal chemistry.

[0123] As used herein, the term "mammal" is used in its ordinary biological sense. Thus, it specifically includes, but is not limited to, primates, including apes (chimpanzees, apes, monkeys) and humans, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, and mice, but also includes many other species.

[0124] As used herein, the term "microbial infection" refers to the invasion of a host organism by pathogenic microorganisms, whether the organism is a vertebrate, invertebrate, fish, plant, bird or mammal. This includes the overgrowth of microorganisms that are normally present in or on the body of a mammal or other organism. More generally, a microbial infection can be any situation in which the presence of a microbial population causes damage to the host mammal. Thus, a mammal is "suffering from" a microbial infection when there is an excessive microbial population in or on the body of a mammal, or when the effects of the presence of a microbial population are damaging the cells or other tissues of the mammal. Specifically, this description applies to bacterial infections. Note that the compounds of the preferred embodiments can also be used to treat microbial growth or contamination of cell cultures or other culture media, or inanimate surfaces or objects, and nothing herein should limit the preferred embodiments to the treatment of higher organisms unless expressly so provided in the claims.

[0125] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, their use in therapeutic compositions is contemplated. In addition, various adjuvants, such as those commonly used in the art, may be included. Considerations for including various components in pharmaceutical compositions are described, for example, in Gilman et al. (eds.) (1990); Goodman and Gilman: The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, which are incorporated herein by reference in their entirety.

[0126] As used herein, the term "subject" refers to a human or non-human mammal, such as a dog, cat, mouse, rat, cow, sheep, pig, goat, non-human primate, or bird, such as a chicken, as well as any other vertebrate or invertebrate.

[0127] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a therapeutic agent that is effective to alleviate one or more symptoms of a disease or condition to a certain extent or to reduce the likelihood of its onset, and includes a cure for the disease or condition. "Cure" means that the symptoms of the disease or condition are eliminated; however, even after a cure is achieved, there may be certain long-term or permanent effects (such as extensive tissue damage).

[0128] As used herein, "treat," "treatment," or "treating" refers to the administration of a pharmaceutical composition for preventive and / or therapeutic purposes. The term "preventive treatment" refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but is susceptible to or otherwise at risk for a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term "therapeutic treatment" refers to administering a treatment to a subject.

[0129] It is understood that when the compounds disclosed herein have unfilled valences, then the valences will be filled with hydrogen and / or deuterium.

[0130] It should be understood that the compounds described herein can be isotopically labeled or labeled by another other means, including but not limited to the use of a chromophore or fluorescent moiety, bioluminescent labeling or chemiluminescent labeling. Substitution with isotopes such as deuterium can provide certain therapeutic advantages resulting from higher metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Each chemical element represented in the compound structure can include any isotope of the element. For example, in the compound structure, a hydrogen atom can be explicitly disclosed or understood to be present in the compound. At any position of the compound where a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium), hydrogen-2 (deuterium) and hydrogen-3 (tritium). Therefore, unless the context clearly provides otherwise, the compounds mentioned herein encompass all potential isotopic forms.

[0131] As used herein, the term "immune checkpoint inhibitor" refers to a molecule (e.g., a small molecule, peptide, polypeptide, protein, antibody fragment, etc.) that acts as an inhibitor (antagonist) of an immune checkpoint pathway. Inhibition of a pathway can include blocking the pathway by binding to a receptor or signaling molecule that is part of the immune checkpoint pathway.

[0132] As used herein, the term "about" refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by up to 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% relative to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. When a value is preceded by the term about, the amount is not intended to be strictly limited to that value, but is intended to include amounts that vary from that value.

[0133] Compound

[0134] Some embodiments provide compounds of formula (I):

[0135]

[0136] In some embodiments, Formula (I) is a pharmaceutically acceptable salt as described herein.

[0137] In some embodiments, Formula (I) is represented by Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id):

[0138]

[0139] In some embodiments, Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id) is a pharmaceutically acceptable salt as described herein.

[0140] Some embodiments provide compounds of formula (II):

[0141]

[0142] In some embodiments, Formula (II) is a pharmaceutically acceptable salt as described herein.

[0143] In some embodiments, Formula (II) is represented by Formula (IIa), Formula (IIb), or Formula (IIc):

[0144]

[0145] In some embodiments, Formula (IIa), Formula (IIb), Formula (IIc), and Formula (IId) may be pharmaceutically acceptable salts as described herein.

[0146] Some embodiments provide compounds of formula (III):

[0147]

[0148] In some embodiments, Formula (III) is a pharmaceutically acceptable salt as described herein.

[0149] In some embodiments, Ring A is

[0150] In some embodiments of compounds of Formula (I) or (Ic), R 1and optionally substituted alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl or L.

[0151] In some embodiments, R 1 In some embodiments, R 1 It is not an ether-linked pyrimidinyl group.

[0152] In some embodiments of compounds of Formula (I), (Ia), (Ib), (II), (IIa), (IIb), or (III), R 2 and optionally substituted alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some embodiments, R 2 is L. In some further embodiments, R 2 is –CH3.

[0153] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IId), or (III), R 3 and optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some further embodiments, R 2 is L. In some further embodiments, R 2 is –CH3.

[0154] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), or (IIa), R 4 and optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 Heteroaryl or L.

[0155] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), or (IIc), R 5can be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl. In some embodiments, R 5 is H, deuterium, halogenated or optionally substituted C1 to C6 alkyl.

[0156] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), or (IIc), R 5′ can be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl. In some embodiments, R 5′ is H, deuterium, halogenated or optionally substituted C1 to C6 alkyl.

[0157] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), (IIc), (IId), or (III), R 6 and optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some embodiments, R 6 Selected from the group consisting of H or fluorine, chlorine or bromine.

[0158] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), R 7and optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some embodiments, R 7 is F, Cl or Br. In some embodiments, R 7 In some embodiments, R 7 can be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl. In some embodiments, R 7 In some embodiments, R 7 is H. In some embodiments, R 7 Selected from the group consisting of H, F, methyl or methoxy. In some embodiments, R 7 H or F.

[0159] In some embodiments of the compound of Formula (IIa), R 8 is selected from H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 In some further embodiments, R 8 is selected from halo, H, deuterium or CH3.

[0160] In some embodiments of compounds of Formula (Id), R 9 It may be selected from hydrogen, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), or -CH2-(optionally substituted C3 to C8 cycloalkyl) 10 In some further embodiments, Z2 is C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, -NR 5 R 5′ , –CH2CH or –CH2CN.

[0161] In some embodiments of compounds of Formula (Id), R 10 It may be selected from hydrogen, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), or -CH2-(optionally substituted C3 to C8 cycloalkyl) 10 In some further embodiments, Z2 is C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, -NR 5 R 5′ , –CH2CH or –CH2CN.

[0162] In some embodiments of the compound of formula (II), R 11 are independently H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some further embodiments, R 11 is selected from halo, H or CH3.

[0163] In some embodiments of the compound of formula (III), R 13and optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C6 alkyl, optionally substituted C1 ... 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl or L. In some embodiments, R 13 It is a C1 to C6 alkyl group.

[0164] In some embodiments of the compound of formula (III), X can be selected from C(R 5 )2、CH(R 5 ), CH2, –O–, In some further embodiments, X is CH2 or -O-. In some further embodiments, X is -O-.

[0165] In some embodiments of compounds of Formula (Id) or (IId), X 1 is N or CH.

[0166] In some embodiments of compounds of Formula (Id), n is 1, 2, 3, or 4.

[0167] In some embodiments of compounds of Formula (I), (Ia), (II), or (IIa), Y 1 Can be selected from C(R 5 )2、CH(R 5 ), CH2, –O–, In some further embodiments, Y 1 is CH2 or -O-. In some further embodiments, Y 1 In some embodiments, Y 1 for In some embodiments of compounds of Formula (I), (Ia), (II), or (IIa), Y 2 Can be selected from C(R 5 )2、CH(R 5 ), CH2, –O–, In some embodiments, Y2 In some embodiments, Y 2 for

[0168] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), L may be selected from -Z1-Z2. In some embodiments of compounds of Formula (III), L may be selected from -Z1-Z2-Z3.

[0169] In some embodiments of the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), Z1 can be selected from –CH2–, –O–, –S–, S═O, –SO2–, C═O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH–SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–、-NHCH2CO-、–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5-, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), or -CH2-(optionally substituted C3 to C8 cycloalkyl) 10 In some further embodiments, Z1 is -CH2-.

[0170] In some embodiments of the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), Z2 can be selected from hydrogen, deuterium, halo, –CH2-, –O-, –S-, S=O, –SO2-, C=O, –CO2-, –NO2, –NH-, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5 –, -NHCH2CO-, –NH–SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5-, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), or -CH2-(optionally substituted C3 to C8 cycloalkyl) 10 In some further embodiments, Z2 is C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, -NR 5 R 5 , -CH2CH or -CH2CN. In some further embodiments, Z2 is an optionally substituted C3 to C8 heterocyclyl. In some embodiments, Z2 is -NR 5 R 5′ In some embodiments, Z1 is -CH2- and Z2 is -NR 5 R 5′ .

[0171] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), Z3 can be selected from hydrogen, deuterium, halo, –COH, –CO2H, –NO2, –CH2CCH, –CH2CN, –NR 5 R 5′ 、–(CO)NH2、–(CO)NR 5 R 5′ 、–SO2-NH2、–R 5 CH3, –R 5 -COH, –R 5 CO2H, –R 5 NH2, –R 5 NH(COH), –R 5 (CO)NH2, –R 5 NH-SO2H, –R 5 SO2-NH2, –CH2R 5 、–OR 5 ,–SO2R 5 –, –CO2R 5 ,–NHR 5 、–NH(CO)R 5 、–(CO)NHR 5 、–NH-SO2R 5 , –SO2-NHR 5, optionally substituted amino, optionally substituted C1 to C4 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), or -CH2-(optionally substituted C3 to C8 cycloalkyl) 10 heteroaryl).

[0172] In some embodiments, Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III) is a compound of the disclosed formula, such as Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or (III), but does not include compounds:

[0173] Some embodiments provide compounds of formula (IV):

[0174]

[0175] In some embodiments, Formula (IV) is a pharmaceutically acceptable salt as described herein.

[0176] In some embodiments of compounds of formula (IV), R6 is hydrogen, fluoro, or chloro.

[0177] In some embodiments of the compound of formula (IV), R 13 Ethyl or -NR A R B , where R A is hydrogen and R B It is a methyl group.

[0178] In some embodiments of the compound of formula (IV), Z2 is -NR 5 R 5 '、

[0179] In some embodiments of the compound of formula (IV), R 5 It is a C1 to C6 alkyl group.

[0180] In some embodiments of the compound of formula (IV), R 5 ' is a C1 to C6 alkyl group.

[0181] In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV) is selected from the compounds of Tables B, C, D, E, and pharmaceutically acceptable salts thereof. Table B. Exemplary compounds of the present disclosure.

[0182]

[0183]

[0184]

[0185]

[0186] Table C. Exemplary compounds of the present disclosure.

[0187]

[0188]

[0189] Table D. Exemplary compounds of the present disclosure.

[0190]

[0191] Table E. Exemplary compounds of the present disclosure.

[0192]

[0193] In some embodiments, the pharmaceutically acceptable salt may be an alkaline metal salt. In some embodiments, the pharmaceutically acceptable salt may be an alkali metal salt. In some embodiments, the pharmaceutically acceptable salt may be an alkaline earth metal salt. In some embodiments, the pharmaceutically acceptable salt may be an ammonium salt.

[0194] synthesis

[0195] The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) described herein, or pharmaceutically acceptable salts thereof, can be prepared in a variety of ways, including those known to those skilled in the art. The routes shown and described herein are illustrative only and are not intended to, and should not be construed to, limit the scope of the claims in any way. One skilled in the art will be able to recognize modifications to the disclosed syntheses and devise alternative routes based on the disclosure herein; all such modifications and alternative routes are within the scope of the claims. Examples of the methods are described in the Examples below.

[0196] Preparation method

[0197] Compounds disclosed herein can be synthesized by the following methods or by modifications of these methods. The method of modification particularly includes temperature, solvent, reagent, etc., and is apparent to those skilled in the art. Generally, in any method for preparing compounds disclosed herein, it may be necessary and / or desirable to protect sensitive or reactive groups on any related molecules. This can be done with the aid of conventional protecting groups, such as Protective Groups in Organic Chemistry (editor JFWMcOmie, Plenum Press, 1973); and those described in Greene and Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which are incorporated herein by reference in their entirety. Protecting groups can be removed in a convenient subsequent stage using methods known in the art. Synthetic chemical transformations that can be used to synthesize useful compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers, 1989, or L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons, 1995, which are incorporated herein by reference in their entirety.

[0198] When the method for preparing the compound disclosed herein produces a mixture of stereoisomers, such isomers can be separated by conventional techniques (such as preparative chiral chromatography). The compound can be prepared in racemic form, or can be synthesized by stereoselectivity or prepared by splitting a single enantiomer. The compound can be decomposed into its component enantiomer by standard techniques, such as by forming a salt with an optically active acid (such as (-)-di-p-toluoyl-d-tartaric acid and / or (+)-di-p-toluoyl-l-tartaric acid) to form a diastereoisomer pair, followed by fractional crystallization and regeneration of the free alkali. It is also possible to use a chiral auxiliary by forming a diastereomeric derivative such as an ester, amide or ketal, then by chromatographic separation and removing the chiral auxiliary to split the compound.

[0199] Pharmaceutical composition

[0200] On the other hand, a pharmaceutical composition is disclosed, which comprises a physiologically acceptable surfactant, carrier, diluent, excipient, smoothing agent, suspending agent, film-forming material and coating aid or a combination thereof; and a compound disclosed herein. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field and are described in, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety. Preservatives, stabilizers, dyes, sweeteners, spices, flavorings, etc. can be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid and parahydroxybenzoates can be added as preservatives. In addition, antioxidants and suspending agents can be used. In various embodiments, alcohols, esters, sulfated aliphatic alcohols, etc. can be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium aluminum methyl silicate, synthetic aluminum silicate, calcium carbonate, sodium bicarbonate, calcium hydrogen phosphate, carboxymethyl cellulose calcium, etc. can be used as excipients; magnesium stearate, talc, hardened oil, etc. can be used as lubricants; coconut oil, olive oil, sesame oil, peanut oil, soybean can be used as suspending agents or lubricants; cellulose acetate phthalate, which is a derivative of carbohydrates such as cellulose or sugar, or methyl acetate-methacrylate copolymer, which is a polyethylene derivative, can be used as a suspending agent; and plasticizers such as phthalates can be used as suspending agents.

[0201] As used herein, the term "pharmaceutical composition" refers to a mixture of a compound disclosed herein with other chemical components (such as a diluent or carrier). Pharmaceutical compositions facilitate administration of a compound to an organism. There are a variety of techniques for administering a compound in the art, including but not limited to oral administration, injection, aerosol, parenteral administration, and topical administration. Pharmaceutical compositions can also be obtained by reacting a compound with an inorganic or organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

[0202] As used herein, the term "carrier" refers to a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier because it facilitates the uptake of many organic compounds into cells or tissues of an organism.

[0203] As used herein, the term "diluent" refers to a chemical compound diluted in water that will dissolve the compound of interest and stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are used as diluents in the art. A commonly used buffered solution is phosphate-buffered saline because it simulates the salt conditions of human blood. Because buffer salts can control the pH of a solution at low concentrations, buffered diluents rarely modify the biological activity of a compound.

[0204] As used herein, the term "physiologically acceptable" refers to a carrier or diluent that does not abrogate the biological activity and properties of the compound.

[0205] As used herein, "excipient" refers to an inert substance added to a pharmaceutical composition to provide, but not limited to, bulk, consistency, stability, binding capacity, lubrication, disintegration capacity, etc. A "diluent" is a type of excipient.

[0206] For each of the compounds described herein, and for each genus or subgenus of compounds described herein, pharmaceutical compositions are also described, comprising the compound alone or with other compounds of the genus or subgenus, or with alternative compounds as described herein, or with one or more alternative pharmaceutically active compounds and one or more pharmaceutically acceptable carriers, diluents, excipients, or combinations thereof. The pharmaceutical compositions described herein can be administered to human patients by themselves or in the form of pharmaceutical compositions mixed with other active ingredients or with carriers, diluents, excipients, or combinations thereof, as in combination therapy. Appropriate formulations depend on the chosen route of administration. The formulation and administration techniques of the compounds described herein are known to those skilled in the art.

[0207] The pharmaceutical compositions disclosed herein can be manufactured in any manner known per se, such as by conventional mixing, dissolving, granulating, dragee preparation, grinding, emulsifying, encapsulating, embedding, or tableting processes. In addition, the active ingredient is present in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein can be provided as salts with pharmaceutically compatible counterions.

[0208] The pharmaceutical compositions described herein can be administered to human patients by themselves or in a pharmaceutical composition mixed with other active ingredients, such as in combination therapy, or mixed with suitable carriers or excipients. Techniques for the formulation and administration of the compounds of the present application can be found in "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, PA, 18th edition, 1990.

[0209] Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical or intestinal administration; parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injection, and intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injection. The compound may also be administered in a sustained or controlled release dosage form, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, etc., for prolonged and / or timed pulse administration at a predetermined rate.

[0210] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, eg, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes.

[0211] Thus, the pharmaceutical compositions used according to the present invention can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and adjuvants that assist in processing the active compound into pharmaceutically acceptable formulations. The appropriate formulation depends on the route of administration selected. Any of the well-known techniques, carriers, and excipients can be used where appropriate and as understood in the art; for example, in Remington's Pharmaceutical Sciences, supra.

[0212] Injectables can be prepared in conventional forms, as liquid solutions or suspensions, solid forms suitable for dissolution or suspension in liquids prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, glucose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine ​​hydrochloride, and the like. In addition, if desired, the injectable pharmaceutical composition may contain a small amount of non-toxic auxiliary substances, such as wetting agents, pH buffers, and the like. Physiologically compatible buffers include, but are not limited to, Hank's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations (e.g., liposomes) may be used.

[0213] For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation.

[0214] Pharmaceutical formulations for parenteral administration (e.g., by bolus injection or continuous infusion) include aqueous solutions of the active compound in water-soluble form. In addition, suspensions of the active compound can be prepared as suitable oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean oil, grapefruit oil, or almond oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to allow the preparation of highly concentrated solutions. Formulations for injection can be present in unit dosage form, for example, in ampoules or multidose containers, with the addition of preservatives. These compositions can take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending agents, stabilizers, and / or dispersants. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle (eg, sterile pyrogen-free water) before use.

[0215] For oral administration, the compound can be easily formulated by combining the active compound with a pharmaceutically acceptable carrier well known in the art. Such carriers enable the compound of the present invention to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. for oral intake by patients to be treated. Oral pharmaceutical preparations can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, and processing the granular mixture to obtain tablets or dragee cores after adding suitable adjuvants (if necessary). Suitable excipients are particularly fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP). If necessary, disintegrants such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or its salts such as sodium alginate can be added. Suitable coatings are provided for dragee cores. For this purpose, concentrated sugar solution can be used, it can optionally contain gum arabic, talcum powder, polyvinyl pyrrolidone, carbopol gel (carbopol gel), polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture.Dye or pigment can be added to tablet or dragee coating, for identifying or characterizing the different combinations of active compound dosage.For this purpose, concentrated sugar solution can be used, it can optionally contain gum arabic, talcum powder, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture.Dye or pigment can be added to tablet or dragee coating, for identifying or characterizing the different combinations of active compound dosage.

[0216] Orally usable pharmaceutical preparations include push-in capsules made from gelatin, and soft sealed capsules made from gelatin and plasticizers such as glycerol or sorbitol. Such push-in capsules can contain active ingredients, which are mixed with fillers such as lactose, adhesives such as starch and / or lubricants such as talc or magnesium stearate and optionally stabilizers. In soft capsules, the active compound can be dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin or liquid polyethylene glycol. In addition, stabilizers can also be added. All formulations for oral administration should be suitable dosages for this type of administration.

[0217] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0218] For administration by inhalation, the compounds for use according to the invention are conveniently delivered in the form of an aerosol spray from pressurized packs or nebulizers, using a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges, for example, of gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.

[0219] Further disclosed herein are various pharmaceutical compositions well known in the pharmaceutical arts for uses including intraocular, intranasal, and intraaural delivery. Suitable penetrants for these uses are generally known in the art. Pharmaceutical compositions for intraocular delivery include aqueous ophthalmic solutions of a water-soluble form of the active compound, such as eye drops or gellan gum (Shedden et al., Clin. Ther., 23(3):440-50 (2001)) or hydrogels (Mayer et al., Ophthalmologica, 210(2):101-3 (1996)); eye ointments; ophthalmic suspensions, such as microparticles suspended in a liquid carrier medium, small polymer particles containing the drug (Joshi, A., J. Ocul. Pharmacol., 10(1):29-45 (1994)), lipid-soluble formulations (Alm et al., Prog. Clin. Biol. Res., 312:447-58 (1989)) and microspheres (Mordenti, Toxicol. Sci., 52(1):101-6 (1999)); and ophthalmic inserts. All of the above references are incorporated herein by reference in their entirety. Suitable pharmaceutical formulations of this type are most commonly and preferably formulated to be sterile, isotonic, and buffered to achieve stability and comfort. Pharmaceutical compositions for intranasal delivery may also include drops and sprays, which are typically prepared to simulate nasal secretions in many respects to ensure that normal ciliary action is maintained. As disclosed in Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety and is well known to those skilled in the art, suitable formulations are most commonly and preferably isotonic, slightly buffered to maintain a pH of 5.5 to 6.5, and most commonly and preferably contain an antimicrobial preservative and appropriate pharmaceutical stabilizer. Pharmaceutical formulations for intraauricular delivery include suspensions and ointments for topical application to the ear. Common solvents for such auricular formulations include glycerol and water.

[0220] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter or other glycerides.

[0221] In addition to the aforementioned formulations, the compound can also be formulated into a depot formulation. Such long-acting formulations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compound can be formulated with a suitable polymeric or hydrophobic material (e.g., as an emulsion in an acceptable oil) or an ion exchange resin, or as a sparingly soluble derivative, e.g., as a sparingly soluble salt.

[0222] For hydrophobic compounds, a suitable pharmaceutical carrier may be a co-solvent system comprising benzyl alcohol, a non-polar surfactant, a water-miscible organic polymer and an aqueous phase. A commonly used co-solvent system is the VPD co-solvent system, which is composed of 3% w / v benzyl alcohol, 8% w / v non-polar surfactant Polysorbate 80 TM A solution consisting of 65% w / v polyethylene glycol 300 and 65% w / v polyethylene glycol 300 is made up to volume in absolute ethanol. Naturally, the proportions of the co-solvent system can be varied significantly without destroying its solubility and toxicity characteristics. In addition, the nature of the co-solvent components can be varied: for example, other low-toxicity non-polar surfactants can be used in place of POLYSORBATE 80. TM The fraction size of polyethylene glycol can be varied; other biocompatible polymers can be substituted for polyethylene glycol, for example, polyvinyl pyrrolidone; and other sugars or polysaccharides can be substituted for glucose.

[0223] Alternatively, other delivery systems for hydrophobic drug compounds can be used. Liposomes and emulsions are examples of delivery vehicles or carriers for well-known hydrophobic drugs. Certain organic solvents, such as dimethyl sulfoxide, can also be used, although usually at the expense of greater toxicity. In addition, the compound can be delivered using a sustained-release system, such as a semipermeable matrix of a solid hydrophobic polymer containing the therapeutic agent. Various sustained-release materials have been established and are well known to those skilled in the art. Depending on its chemical properties, sustained-release capsules may release the compound for several weeks to more than 100 days. Depending on the chemical properties and biological stability of the therapeutic agent, other protein stabilization strategies can be adopted.

[0224] Agents intended for intracellular administration can be administered using techniques well known to those of ordinary skill in the art. For example, such agents can be encapsulated in liposomes. When liposomes are formed, all molecules present in the aqueous solution are incorporated into the aqueous interior. The liposome contents are protected from the external microenvironment, but because the liposomes fuse with the cell membrane, they can be effectively delivered to the cytoplasm. Liposomes can be coated with tissue-specific antibodies. The liposomes will target the desired organ and be selectively taken up by it. Alternatively, small hydrophobic organic molecules can be administered directly into the cell.

[0225] Additional therapeutic or diagnostic agents may be incorporated into the pharmaceutical composition.Alternatively or additionally, the pharmaceutical composition may be combined with other compositions containing other therapeutic or diagnostic agents.

[0226] Parenteral pharmaceutical compositions

[0227] To prepare a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous, etc.), 0.1 mg to 120 mg of a water-soluble salt of a compound of the preferred embodiment / soluble substance itself / solubilized complex is dissolved in sterile water and then mixed with 10 μL of 0.9% sterile saline. The mixture is incorporated into a dosage unit form suitable for administration by injection.

[0228] Injectable pharmaceutical composition

[0229] To prepare an injectable formulation, 0.1 mg to 100 mg of a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), (IIc), (III), or (IV), 2.0 mL of a 0.4 M sodium acetate buffer solution, 1 N HCl, or 1 M NaOH (1 M) (q.s. to the appropriate pH), and water (distilled, sterile) (q.s. to 20 mL) are mixed. All of the above ingredients, except the water, are combined and stirred, and if necessary, slightly heated. A sufficient amount of water is then added.

[0230] Oral pharmaceutical composition

[0231] To prepare a pharmaceutical composition for oral delivery, 0.1 mg to 120 mg of the compound of the Examples is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit, such as a hard gelatin capsule, or 0.1 mg to 120 mg of the compound is granulated with a binder solution, such as a starch solution, and a suitable diluent, such as microcrystalline cellulose, a disintegrant, such as croscarmellose sodium, and the resulting mixture is dried and a lubricant is added and compressed into tablets suitable for oral administration.

[0232] Sublingual (hard lozenge) pharmaceutical composition

[0233] To prepare a pharmaceutical composition for oral delivery, such as a hard lozenge, 0.1 mg to 120 mg of a compound of the preferred embodiment is mixed with 420 mg of powdered sugar / mannitol / xylitol or sugar that provides negative heat of dissolution to the system, 1.6 mL of light corn syrup, 2.4 mL of distilled water, and 0.42 mL of peppermint extract or other flavoring. The mixture is blended and poured into a mold to form a lozenge suitable for oral administration.

[0234] Fast-disintegrating sublingual tablets

[0235] A fast-disintegrating sublingual tablet is prepared by mixing 48.5% by weight of a compound of a preferred embodiment, 20% by weight of microcrystalline cellulose (KG-802), 24.5% by weight of mannitol or modified glucose or a combination thereof to help the compressed tablet dissolve faster in the mouth, 5% by weight of low-substituted hydroxypropyl cellulose (50 μm), and 2% by weight of magnesium stearate. Tablets are prepared by direct compression (AAPS PharmSciTech. 2006; 7(2): E41). The total weight of the compressed tablets is maintained at 150 mg. The formulation is prepared by mixing the amount of the compound of the preferred embodiment with the total amount of microcrystalline cellulose (MCC) and mannitol / modified glucose or a combination thereof and two-thirds of the low-substituted hydroxypropyl cellulose (L-HPC) using a three-dimensional hand mixer (Inversina, Bioengineering AG, Switzerland) for 4.5 minutes. All of the magnesium stearate (MS) and the remaining one-third of the L-HPC are added 30 seconds before the end of mixing.

[0236] Inhaled pharmaceutical composition

[0237] To prepare a pharmaceutical composition for inhalation delivery, 0.1 mg to 100 mg of a compound of the preferred embodiments is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery device suitable for inhalation administration, such as a nebulizer.

[0238] Nebulizer suspension pharmaceutical composition

[0239] In another embodiment, a compound of the preferred embodiment (0.1 mg to 100 mg) is suspended in sterile water (100 mL); Span 85 (1 g) is added, followed by glucose (5.5 g) and ascorbic acid (10 mg). Benzalkonium chloride (3 mL of a 1:750 aqueous solution) is added and the pH is adjusted to 7 with phosphate buffer. The suspension is packaged in a sterile nebulizer.

[0240] Transdermal patch pharmaceutical composition

[0241] To prepare a pharmaceutical composition for transdermal delivery, 0.1 mg to 100 mg of a compound of the preferred embodiment is embedded or deposited in a patch having a single adhesive surface. The resulting patch is then attached to the skin via the adhesive surface for transdermal administration.

[0242] Topical gel pharmaceutical composition

[0243] To prepare a pharmaceutical topical gel composition, 0.1 mg to 100 mg of a compound of the preferred embodiments is mixed with 1.75 g of hydroxypropylcellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate, and 100 mL of purified alcohol, USP. The resulting gel mixture is then incorporated into a container suitable for topical administration, such as a test tube.

[0244] ophthalmic solution

[0245] To prepare a pharmaceutical ophthalmic solution composition, 0.1 mg to 100 mg of a compound of the preferred embodiment is mixed with 0.9 g of NaCl in 100 mL of purified water and filtered using a 0.2 micron filter. The resulting isotonic solution is then incorporated into an ophthalmic delivery device suitable for ophthalmic administration, such as an eye drop container.

[0246] nasal spray solution

[0247] To prepare the pharmaceutical nasal spray solution, 0.1 mg to 100 mg of a compound of the preferred examples is mixed with 30 mL of 0.05 M phosphate buffer solution (pH 4.4).The solution is placed in a nasal applicator designed to deliver 100 μl of spray per application.

[0248] Immune checkpoint inhibitors

[0249] In some embodiments, one or more immune checkpoint inhibitors can be co-administered with a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), (IIc), (III) or (IV). Pardoll provides a review describing immune checkpoint pathways and blocking such pathways with immune checkpoint inhibitor compounds in Nature Reviews Cancer (April 2012), pp. 252-264, which is incorporated herein by reference in its entirety. Immune checkpoint inhibitor compounds exhibit anti-tumor activity by blocking one or more of the endogenous immune checkpoint pathways that downregulate anti-tumor immune responses. Inhibition or blocking of immune checkpoint pathways generally involves inhibiting the interaction of checkpoint receptors and ligands with immune checkpoint inhibitor compounds to reduce or eliminate the downregulation signal and result in a reduction in the anti-tumor response.

[0250] In some embodiments of the present disclosure, immune checkpoint inhibitor compounds inhibit the signaling interaction between immune checkpoint receptors and the corresponding ligands of immune checkpoint receptors. Immune checkpoint inhibitor compounds can work by inhibiting (antagonizing) immune checkpoint receptors (some examples of receptors include CTLA-4, PD-1, LAG-3, TIM-3, BTLA and KIR) or by inhibiting the ligands of immune checkpoint receptors (some examples of ligands include PD-L1 and PD-L2) to block the activation of immune checkpoint pathways. In such embodiments, the effect of the immune checkpoint inhibitor compound is to reduce or eliminate the downregulation of certain aspects of the anti-tumor response of the immune system in the tumor microenvironment.

[0251] The programmed death 1 (PD-1) protein is an inhibitory member of the expanded CD28 / CTLA-4 family of T cell regulatory factors (Okazaki et al. (2002) Curr Opin Immunol 14:391779-82; Bennett et al. (2003) J. Immunol. 170:711-8; these documents are incorporated herein by reference in their entirety). Other members of the CD28 family include CD28, CTLA-4, ICOS, and BTLA. PD-1 is believed to exist in a monomeric form and lacks the unpaired cysteine ​​residues characteristic of other CD28 family members. PD-1 is expressed on activated B cells, T cells, and monocytes.

[0252] The PD-1 gene encodes a 55kDa type I transmembrane protein (Agata et al. (1996) Int Immunol. 8: 765-72, which is incorporated herein by reference in its entirety). Although structurally similar to CTLA-4, PD-1 lacks the MYPPY motif that is important for B7-1 and B7-2 binding. Two ligands for PD-1 have been identified, PD-L1 (B7-H1) and PD-L2 (B7-DC), which have been shown to downregulate T cell activation after binding to PD-1 (Freeman et al. (2000) J. Exp. Med. 192: 1027-34; Carter et al. (2002) Eur. J. Immunol. 32: 634-43; these documents are incorporated herein by reference in their entirety). Both PD-L1 and PD-L2 are B7 homologs that bind to PD-1 but not to other CD28 family members. PD-L1 is abundant in a variety of human cancers (Dong et al. (2002) Nat. Med. 8:787-9, which is herein incorporated by reference in its entirety).

[0253] PD-1 is considered an immunosuppressive protein that negatively regulates TCR signaling (Ishida, Y. et al. (1992) EMBO J. 11:3887-3895; Blank, C. et al. (Epub 2006 Dec 29) Immunol. Immunother. 56(5):739-745; each of which is incorporated herein by reference in its entirety). The interaction between PD-1 and PD-L1 can serve as an immune checkpoint, which can lead to, for example, a decrease in tumor-infiltrating lymphocytes, a decrease in T cell receptor-mediated proliferation, and / or immune evasion of cancer cells (Dong et al. (2003) J. Mol. Med. 81:281-7; Blank et al. (2005) Cancer Immunol. Immunother. 54:307-314; Konishi et al. (2004) Clin. Cancer Res. 10:5094-100; each of which is incorporated herein by reference in its entirety). Immunosuppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1 or PD-L2; this effect is additive when the interaction of PD-1 with PD-L2 is also blocked (Iwai et al. (2002) Proc. Nat'l. Acad. Sci. USA 99:12293-7; Brown et al. (2003) J. Immunol. 170:1257-66; each of which is incorporated herein by reference in its entirety).

[0254] The immune checkpoint receptor cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is expressed on T cells and participates in signaling pathways that reduce the level of T cell activation. It is believed that CTLA-4 can downregulate T cell activation through competitive binding and sequestration of CD80 and CD86. In addition, CTLA-4 has been shown to be involved in enhancing T 调节 Immunosuppressive activity of cells.

[0255] The immune checkpoint receptor programmed death 1 (PD-1) is expressed by activated T cells after prolonged exposure to antigen. Binding of PD-1 to its known binding partners, PD-L1 and PD-L2, occurs primarily within the tumor microenvironment and leads to downregulation of anti-tumor-specific T cell responses. Both PD-L1 and PD-L2 are known to be expressed on tumor cells. Expression of PD-L1 and PD-L2 on tumors is associated with decreased survival outcomes.

[0256] The immune checkpoint receptor T-cell membrane protein 3 (TIM-3) is expressed on Th1 and Tc1 cells, but not on other T cells. The interaction of TIM-3 with its ligand galectin-9 generates a Th1 cell death signal. TIM-3 has been reported to play a role in maintaining T cell exhaustion, and TIM-3 blockade has been shown to restore the activity of exhausted T cells.

[0257] The immune checkpoint receptor B and T lymphocyte attenuator (BTLA) receptor is expressed on resting and activated B cells and T cells. When bound to its ligand HVEM (herpes virus entry mediator), activation of BTLA leads to downregulation of both T cell activation and proliferation. HVEM is expressed by certain tumors (e.g., melanoma) and tumor-associated endothelial cells.

[0258] Immune checkpoint receptors known as killer cell immunoglobulin-like receptors (KIR) are a polymorphic family of receptors expressed on NK cells and some T cells and act as regulators of immune tolerance associated with natural killer (NK) cells. Blocking certain KIR receptors with inhibitory compounds can promote tumor destruction by increasing the activity of NK cells.

[0259] In some embodiments of the present disclosure, the immune checkpoint inhibitor compound is a small organic molecule (molecular weight less than 1000 Daltons), a peptide, a polypeptide, a protein, an antibody, an antibody fragment, or an antibody derivative. In some embodiments, the immune checkpoint inhibitor compound is an antibody. In some embodiments, the antibody is a monoclonal antibody, particularly a human or humanized monoclonal antibody.

[0260] Monoclonal antibodies, antibody fragments and antibody derivatives for blocking immune checkpoint pathways can be prepared by any of several methods known to those of ordinary skill in the art, including but not limited to somatic cell hybridization technology and hybridoma methods. The generation of hybridomas is described in Antibodies, A Laboratory Manual, Harlow and Lane, 1988, Cold Spring Harbor Publications, New York, which is incorporated herein by reference in its entirety. Human monoclonal antibodies can be identified and isolated by screening phage display libraries of human immunoglobulin genes, and the screening method is described in, for example, U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,698, 6,582,915 and 6,593,081, which are incorporated herein by reference in their entirety. Monoclonal antibodies can be prepared using the general method described in U.S. Patent No. 6,331,415 (Cabilly), which is incorporated herein by reference in its entirety.

[0261] As an example, you can use the XenoMouse TM Human monoclonal antibodies are produced using hybridomas of B cells from XenoMouse (Abgenix, Freemont, Calif.), or from XenoMouse-derived murine hosts with functional human immunoglobulin genes, as described in U.S. Patent No. 6,162,963 (Kucherlapati), which is incorporated herein by reference in its entirety.

[0262] Methods for preparing and using immune checkpoint antibodies are described in the following explanatory publications. The preparation and therapeutic use of anti-CTLA-4 antibodies are described in U.S. Patent No. 7,229,628 (Allison), U.S. Patent No. 7,311,910 (Linsley), and U.S. Patent No. 8,017,144 (Korman), which are incorporated herein by reference in their entirety. The preparation and therapeutic use of anti-PD-1 antibodies are described in U.S. Patent No. 8,008,449 (Korman) and U.S. Patent Application No. 2011 / 0271358 (Freeman), which are incorporated herein by reference in their entirety. The preparation and therapeutic use of anti-PD-L1 antibodies are described in U.S. Patent No. 7,943,743 (Korman), which is incorporated herein by reference in its entirety. The preparation and therapeutic use of anti-TIM-3 antibodies are described in U.S. Patent No. 8,101,176 (Kuchroo) and U.S. Patent No. 8,552,156 (Tagayanagi), which are incorporated herein by reference in their entirety. The preparation and therapeutic use of anti-LAG-3 antibodies are described in U.S. Patent Application No. 2011 / 0150892 (Thudium) and International Publication No. WO2014 / 008218 (Lonberg), which are incorporated herein by reference in their entirety. The preparation and therapeutic use of anti-KIR antibodies are described in U.S. Patent No. 8,119,775 (Moretta), which is incorporated herein by reference in its entirety. The preparation of antibodies that block the inhibitory pathway regulated by BTLA (anti-BTLA antibodies) is described in U.S. Patent No. 8,563,694 (Mataraza), which is incorporated herein by reference in its entirety.

[0263] In some embodiments, one or more immune checkpoint inhibitors are inhibitors of PD-1, PD-L1, or CTLA-4. In some embodiments, the immune checkpoint inhibitor is a PD-1 inhibitor. In some embodiments, the immune checkpoint inhibitor is a binding ligand for PD-L1. In some embodiments, the immune checkpoint inhibitor is a PD-L1 inhibitor. In some embodiments, the immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0264] In some embodiments, one or more immune checkpoint inhibitors as described herein include a first immune checkpoint inhibitor and a second immune checkpoint inhibitor, wherein the first immune checkpoint inhibitor is different from the second immune checkpoint inhibitor. In some embodiments, the first immune checkpoint inhibitor and the second immune checkpoint inhibitor are independently inhibitors of PD-1, PD-L1, or CTLA-4. In some embodiments, the first immune checkpoint inhibitor is a PD-1 inhibitor and the second immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0265] In some embodiments, the immune checkpoint inhibitor is pembrolizumab, nivolumab, cemiplizumab, atezolizumab, avelumab, pembrolizumab, pidilizumab, ipilimumab, BMS 936559, durvalumab, or any combination thereof. In some embodiments, one or more immune checkpoint inhibitors may include an anti-PD-1 HuMAb selected from 17D8, 2D3, 4H1, 5C4 (also referred to herein as nivolumab), 4A1 1, 7D3, and 5F4, all of which are described in U.S. Patent No. 8,008,449, which is incorporated herein by reference in its entirety. In some embodiments, the anti-PD-1 HuMAb may be selected from 3G10, 12A4 (also referred to herein as BMS-936559), 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7, and 13G4, all of which are described in U.S. Pat. No. 7,943,743, which is incorporated herein by reference in its entirety.

[0266] In some embodiments, one or more immune checkpoint inhibitors can be incorporated into a pharmaceutically acceptable formulation. In some embodiments, one or more immune checkpoint inhibitors are incorporated into a pharmaceutically acceptable aqueous formulation. Examples of acceptable aqueous formulations include isotonic buffered saline solutions adjusted to a pH of 4.5-8, such as lactated Ringer's solution.

[0267] In some embodiments, the immune checkpoint inhibitor compound is incorporated into a pharmaceutically acceptable liposome formulation, wherein the formulation is a passive or targeted liposome formulation. Examples of methods for preparing suitable antibody liposome formulations are described in U.S. Patent No. 5,399,331 (Loughrey), U.S. Patent No. 8,304,565 (Wu), and U.S. Patent No. 7,780,882 (Chang), which are incorporated herein by reference in their entirety.

[0268] In some embodiments, one or more immune checkpoint inhibitors may be antibodies. In some embodiments, the antibody is a dried lyophilized solid that is reconstituted with an aqueous reconstitution solvent before use. In some embodiments, the antibody is incorporated into a pharmaceutically acceptable formulation, and the pharmaceutically acceptable formulation is injected directly into the tumor. In some embodiments, the immune checkpoint inhibitor antibody is incorporated into a pharmaceutically acceptable formulation, and the pharmaceutically acceptable formulation is injected into the peritumoral area surrounding the tumor. The peritumoral area may contain anti-tumor immune cells. In some embodiments, the antibody is incorporated into a pharmaceutically acceptable formulation, and the pharmaceutically acceptable formulation is administered by intravenous injection or infusion. In some embodiments, the immune checkpoint inhibitor antibody is incorporated into a pharmaceutically acceptable formulation, and the pharmaceutically acceptable formulation is administered by subcutaneous injection or intradermal injection. In some embodiments, the antibody is incorporated into a pharmaceutically acceptable formulation, and the pharmaceutically acceptable formulation is administered by intraperitoneal injection or lavage.

[0269] The precise amount of the immune checkpoint inhibitor compound incorporated into a particular method or therapeutic combination of the present disclosure may vary according to factors known in the art, such as, for example, the subject's physical and clinical state, the method of administration, the content of the formulation, the physical and chemical properties of the immune checkpoint inhibitor compound, the intended dosing regimen or sequence. However, one of ordinary skill in the art can readily determine the appropriate amount with due consideration of these factors.

[0270] Treatment methods / uses

[0271] Aspects disclosed herein relate to administering to a subject in need thereof an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more compounds as described herein, such as one or more compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof.

[0272] As disclosed elsewhere herein, some embodiments relate to treating a disease or condition, such as cancer, by administering a compound or composition as disclosed herein. It is not always necessary to identify a subject who receives a compound or composition as disclosed herein to improve the health of the subject before receiving the first treatment of the compound or composition. For example, before showing any signs of a disease or condition, it can be predetermined that the subject will suffer from a disease or condition, such as cancer. Alternatively, if the subject is at risk or does not develop a disease or condition such as cancer (for example, once the patient shows symptoms of another disease or condition associated with cancer), he or she can receive preventive treatment. Therefore, in some embodiments, the compound or composition can be administered to the subject after the subject receives early diagnosis. In certain embodiments, not every subject is a candidate for such administration, and it may be necessary to identify the treatment subject. It should be understood that the patient's selection depends on many factors within the scope of the ordinary physician's skills. Therefore, some embodiments disclosed herein further include identifying the subject as a subject who will benefit from administering an effective amount of at least one compound or composition to extend life, increase survival time, or extend survival.

[0273] In other aspects, the present disclosure relates to a method for treating, preventing, or prophylactic cancer, which can include administering to a subject in need thereof an effective amount of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising a compound described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof). In certain embodiments, the cancer can be selected from brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, prostate cancer, kidney cancer, colorectal cancer, melanoma, or leukemia. In further or additional embodiments, the cancer is brain cancer or adrenocortical cancer. In further or additional embodiments, the cancer is breast cancer. In further or additional embodiments, the cancer is ovarian cancer. In further or additional embodiments, the cancer is pancreatic cancer. In further or additional embodiments, the cancer is gastric cancer. In further or additional embodiments, the cancer is prostate cancer. In further or additional embodiments, the cancer is kidney cancer. In further or additional embodiments, the cancer is colorectal cancer. In further or additional embodiments, the cancer is myeloid leukemia. In further or additional embodiments, the cancer is glioblastoma. In further or additional embodiments, the cancer is follicular lymphoma. In further or additional embodiments, the cancer is pre-B acute leukemia. In further or additional embodiments, the cancer is chronic lymphocytic B-leukemia. In further or additional embodiments, the cancer is mesothelioma. In further or additional embodiments, the cancer is a small cell lineage cancer. In further or additional embodiments, the cancer is melanoma.

[0274] Some embodiments relate to a method of inhibiting the proliferation of a cell having a RAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a RAS mutation. Some embodiments relate to a method of inducing apoptosis in a cell having a RAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. Some embodiments relate to a method of inhibiting the proliferation of a cell having a KRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a KRAS mutation. Some embodiments relate to a method of inducing apoptosis in a cell having a KRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. Some embodiments relate to a method of inhibiting the proliferation of a cell having a NRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a NRAS mutation. Some embodiments relate to a method of inducing apoptosis in a cell having a RAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a HRAS mutation. Some embodiments relate to a method of inducing apoptosis in a cell having a RAS mutation, the method comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof. In some embodiments, the KRAS mutation is located at codons 12, 13, 59, 61, and / or 146.In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, and Q61H. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, G13V, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, K117R, K117E, A146P, A146T, and A146V.

[0275] In certain embodiments, the cancer is resistant to treatment with a MEK protein kinase inhibitor. In other embodiments, the cancer is resistant to treatment with a RAF protein kinase inhibitor. In further embodiments, the resistance is acquired. In other embodiments, the resistance is de novo. In further or additional embodiments, the cancer is resistant to an anticancer agent.

[0276] In some aspects, provided herein are compounds or pharmaceutical compositions and methods for treating cancer comprising a therapeutically effective amount of a dual MEK protein kinase inhibitor. In certain embodiments, the administration of a dual MEK protein kinase inhibitor provides an increase in the area under the serum concentration time curve (AUC) of the dual MEK protein kinase inhibitor. In certain embodiments, cancer is resistant to treatment with RAF protein kinase inhibitors. In further embodiments, cancer is resistant to RAF protein kinase inhibitors, and RAF protein kinase inhibitors include A-RAF inhibitors, B-RAF inhibitors, or C-RAF inhibitors. In further embodiments, cancer is resistant to RAF protein kinase inhibitors, and RAF protein kinase inhibitors include B-RAF inhibitors.

[0277] In some embodiments, the resistant cancer is pancreatic cancer, melanoma, colon cancer, lung cancer, or gastric cancer. In further embodiments, the resistant cancer is pancreatic cancer. In yet other embodiments, the resistant cancer is gastric cancer. In alternative embodiments, provided herein are drug combinations and methods for resensitizing cancer cells in a patient having or suspected of having a cancer resistant to an anticancer agent to treatment, the method comprising the step of administering to the patient a therapeutically effective amount of a dual MEK inhibitor as disclosed herein.

[0278] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof is co-administered with a CTLA-4 receptor inhibitor compound. In some embodiments, a compound of Formula (I) is co-administered with a PD-1 or PD-L1 receptor inhibitor compound.

[0279] In some embodiments, the method comprises treating a subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a LAG-3 receptor inhibitor compound. In some embodiments, the method comprises treating a subject by co-administering a therapeutically effective amount of a compound of Formula (I) and a TIM-3 receptor inhibitor compound. In some embodiments, the method comprises treating a subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a BTLA receptor inhibitor compound. In some embodiments, the method comprises treating a subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a KIR receptor inhibitor compound. In some embodiments, the method comprises treating the subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, and a PD-L1 inhibitor compound. In some embodiments, the method comprises treating the subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, and a PD-L2 inhibitor compound.

[0280] In some embodiments of the present disclosure, the method comprises treating the subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an immune checkpoint pathway blocking antibody. In some embodiments, the method comprises treating the subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-CTLA-4 receptor antibody. In some embodiments, the method comprises treating the subject by co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-PD-1 receptor antibody.

[0281] In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-LAG-3 receptor antibody to a subject having a tumor. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-TIM-3 receptor antibody to a subject having a tumor. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-BTLA receptor antibody to a subject having a tumor. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-KIR receptor antibody to a subject having a tumor. In some embodiments, the anti-KIR receptor antibody is lirilumab. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-PD-1 antibody to a subject having a tumor. In some embodiments, the anti-PD-1 antibody is pembrolizumab, pidilizumab, or nivolumab. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-PD-L1 antibody to a subject having a tumor. In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an anti-PD-L2 antibody to a subject having a tumor.In some embodiments, the method comprises co-administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, and an anti-CTLA-4 antibody to a subject having a tumor. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

[0282] In some embodiments, a method comprises co-administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor for treating, preventing, or ameliorating a cancer or tumor in a subject by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor. In some embodiments, the subject is resistant to prior treatment with only an immune checkpoint inhibitor.

[0283] In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a PD-1 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a PD-L1 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a PD-L2 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a CTLA-4 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof, a PD-1 inhibitor, and a CTLA-4 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a LAG-3 inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a KIR inhibitor. In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof and a TIM-3 inhibitor.In some embodiments, a method for treating a subject having cancer or a tumor comprises administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, and a BTLA inhibitor.

[0284] In some embodiments, a method for treating a subject comprises treating a subject that exhibits resistance to a PD-1 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, a method comprises treating a subject that exhibits resistance to a PD-L1 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, a method comprises treating a subject that exhibits resistance to a PD-L2 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, a method includes treating a subject who exhibits resistance to a CTLA-4 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, the method includes administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof when the subject exhibits resistance to two different immune checkpoint inhibitors. The two different immunosuppressants can be selected from CTLA-4 receptor inhibitors, PD-1 receptor inhibitors, LAG-3 receptor inhibitors, TIM-3 receptor inhibitors, BTLA receptor inhibitors, KIR receptor inhibitors, PD-L1 inhibitors, or PD-L2 inhibitors. In some embodiments, a method comprises treating a subject who exhibits resistance to a PD-1 inhibitor and a CTLA-4 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof. In some embodiments, a method comprises treating a subject who exhibits resistance to a PD-L1 inhibitor and a CTLA-4 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof.In some embodiments, a method comprises treating a subject that exhibits resistance to a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof.

[0285] Some embodiments disclosed herein relate to a method of treating a mammal having a disease, which method can include administering to a subject in need thereof an effective amount of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising a compound described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof). Other embodiments disclosed herein relate to a method of treating a subject having cancer cachexia, which method can include administering to the subject an effective amount of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof), or any pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof).

[0286] Some embodiments described herein relate to the use of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for ameliorating and / or treating cancer or a cancer condition (such as cancer cachexia), which may comprise administering to a subject an effective amount of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (Iib), (Iic), (Iid), (III), (IV), or a pharmaceutically acceptable salt thereof). Still other embodiments described herein relate to one or more compounds described herein (such as compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or pharmaceutically acceptable salts thereof), which can be used to ameliorate and / or treat cancer or a cancer condition (such as cancer cachexia) by administering to a subject an effective amount of one or more compounds described herein or pharmaceutically acceptable salts thereof.

[0287] Some embodiments disclosed herein relate to methods of ameliorating and / or treating cancer, which methods may include contacting cancer cells with an effective amount of one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising one or more compounds described herein (such as a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof). In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can act as an inhibitor of MEK. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can act as an inhibitor of ERK. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (Iib), (Iic), (Iid), (III), (IV) or a pharmaceutically acceptable salt thereof can act as a STAT3 (pSER-727) inhibitor. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can reduce inflammatory cachexia and muscle atrophy.

[0288] In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can be administered once daily as a single dose. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can be administered in multiple doses, more than once per day. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can be administered once daily. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can be administered twice daily. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, can be administered three times daily. In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, can be administered four times daily.

[0289] In some aspects, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof can inhibit abnormal cell growth. In some embodiments, the abnormal cell growth occurs in a mammal. Methods for inhibiting abnormal cell growth can include administering an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (Iib), (Iic), (Iid), (III), (IV) or a pharmaceutically acceptable salt thereof, wherein abnormal cell growth is inhibited. Methods for inhibiting abnormal cell growth in a mammal can include administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof to a mammal, wherein the amount of the compound is effective to inhibit abnormal cell growth in the mammal.

[0290] In other aspects, the present invention relates to a method for degrading, inhibiting the growth of, or killing cancer cells, comprising contacting the cells with a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, that is effective for degrading, inhibiting the growth of, or killing the cells. In some embodiments, the cancer cells include brain cancer cells, breast cancer cells, lung cancer cells, ovarian cancer cells, pancreatic cancer cells, gastric cancer cells, prostate cancer cells, renal cancer cells, melanoma cells, or colorectal cancer cells.

[0291] In some embodiments, cancer cells are degraded. In some embodiments, 1% of cancer cells are degraded. In further or additional embodiments, 2% of cancer cells are degraded. In further or additional embodiments, 3% of cancer cells are degraded. In further or additional embodiments, 4% of cancer cells are degraded. In further or additional embodiments, 5% of cancer cells are degraded. In further or additional embodiments, 10% of cancer cells are degraded. In further or additional embodiments, 20% of cancer cells are degraded. In further or additional embodiments, 25% of cancer cells are degraded. In further or additional embodiments, 30% of cancer cells are degraded. In further or additional embodiments, 40% of cancer cells are degraded. In further or additional embodiments, 50% of cancer cells are degraded. In further or additional embodiments, 60% of cancer cells are degraded. In further or additional embodiments, 70% of cancer cells are degraded. In further or additional embodiments, 75% of cancer cells are degraded. In further or additional embodiments, 80% of cancer cells are degraded. In further or additional embodiments, 90% of cancer cells are degraded. In further or additional embodiments, 100% of the cancer cells are degraded. In further or additional embodiments, substantially all of the cancer cells are degraded.

[0292] In some embodiments, cancer cells are killed. In further or additional embodiments, 1% of cancer cells are killed. In further or additional embodiments, 2% of cancer cells are killed. In further or additional embodiments, 3% of cancer cells are killed. In further or additional embodiments, 4% of cancer cells are killed. In further or additional embodiments, 5% of cancer cells are killed. In further or additional embodiments, 1.0% of cancer cells are killed. In further or additional embodiments, 20% of cancer cells are killed. In further or additional embodiments, 25% of cancer cells are killed. In further or additional embodiments, 30% of cancer cells are killed. In further embodiments, 40% of cancer cells are killed. In further or additional embodiments, 50% of cancer cells are killed. In further or additional embodiments, 60% of cancer cells are killed. In further or additional embodiments, 70% of cancer cells are killed. In further or additional embodiments, 75% of cancer cells are killed. In further or additional embodiments, 80% of cancer cells are killed. In further or additional embodiments, 90% of the cancer cells are killed. In further or additional embodiments, 100% of the cancer cells are killed. In further or additional embodiments, substantially all of the cancer cells are killed.

[0293] In further or additional embodiments, the growth of cancer cells is inhibited. In further or additional embodiments, the growth of cancer cells is inhibited by about 1%. In further or additional embodiments, the growth of cancer cells is inhibited by about 2%. In further or additional embodiments, the growth of cancer cells is inhibited by about 3%. In further or additional embodiments, the growth of cancer cells is inhibited by about 4%. In further or additional embodiments, the growth of cancer cells is inhibited by about 5%. In further or additional embodiments, the growth of cancer cells is inhibited by about 10%. In further or additional embodiments, the growth of cancer cells is inhibited by about 20%. In further or additional embodiments, the growth of cancer cells is inhibited by about 25%. In further or additional embodiments, the growth of cancer cells is inhibited by about 30%. In further or additional embodiments, the growth of cancer cells is inhibited by about 40%. In further or additional embodiments, the growth of cancer cells is inhibited by about 50%. In further or additional embodiments, the growth of cancer cells is inhibited by about 60%. In further or additional embodiments, the growth of cancer cells is inhibited by about 70%. In further or additional embodiments, the growth of cancer cells is inhibited by about 75%. In further or additional embodiments, the growth of cancer cells is inhibited by about 80%. In further or additional embodiments, the growth of cancer cells is inhibited by about 90%. In further or additional embodiments, the growth of cancer cells is inhibited by about 100%.

[0294] In some embodiments, the size of a tumor is reduced by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof. In further or additional embodiments, the size of the tumor is reduced by at least 1%. In further or additional embodiments, the size of the tumor is reduced by at least 2%. In further or additional embodiments, the size of the tumor is reduced by at least 3%. In further or additional embodiments, the size of the tumor is reduced by at least 4%. In further or additional embodiments, the size of the tumor is reduced by at least 5%. In further or additional embodiments, the size of the tumor is reduced by at least 10%. In further or additional embodiments, the size of the tumor is reduced by at least 20%. In further or additional embodiments, the size of the tumor is reduced by at least 25%. In further or additional embodiments, the size of the tumor is reduced by at least 30%. In further or additional embodiments, the size of the tumor is reduced by at least 40%. In further or additional embodiments, the size of the tumor is reduced by at least 50%. In further or additional embodiments, the size of the tumor is reduced by at least 60%. In further or additional embodiments, the size of the tumor is reduced by at least 70%. In further or additional embodiments, the size of the tumor is reduced by at least 75%. In further or additional embodiments, the size of the tumor is reduced by at least 80%. In further or additional embodiments, the size of the tumor is reduced by at least 85%. In further or additional embodiments, the size of the tumor is reduced by at least 90%. In further or additional embodiments, the size of the tumor is reduced by at least 95%. In further or additional embodiments, the tumor is eradicated. In some embodiments, the size of the tumor does not increase.

[0295] In some embodiments, tumor proliferation is reduced by administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), or (IV), or a pharmaceutically acceptable salt thereof. In some embodiments, tumor proliferation is reduced by at least 1%. In some embodiments, tumor proliferation is reduced by at least 2%. In some embodiments, tumor proliferation is reduced by at least 3%. In some embodiments, tumor proliferation is reduced by at least 4%. In some embodiments, tumor proliferation is reduced by at least 5%. In some embodiments, tumor proliferation is reduced by at least 10%. In some embodiments, tumor proliferation is reduced by at least 20%. In some embodiments, tumor proliferation is reduced by at least 25%. In some embodiments, tumor proliferation is reduced by at least 30%. In some embodiments, tumor proliferation is reduced by at least 40%. In some embodiments, tumor proliferation is reduced by at least 50%. In some embodiments, tumor proliferation is reduced by at least 60%. In some embodiments, tumor proliferation is reduced by at least 70%. In some embodiments, tumor proliferation is reduced by at least 75%. In some embodiments, tumor proliferation is reduced by at least 75%. In some embodiments, tumor proliferation is reduced by at least 80%. In some embodiments, tumor proliferation is reduced by at least 90%. In some embodiments, tumor proliferation is reduced by at least 95%. In some embodiments, tumor proliferation is prevented.

[0296] Application method

[0297] Compound or pharmaceutical composition can be administered to the patient by any suitable means. Non-limiting examples of methods of administration include, among others, (a) administration by oral route, including administration in the form of capsules, tablets, granules, sprays, syrups or other such forms; (b) administration by non-oral routes such as rectal, vaginal, intraurethral, ​​intraocular, intranasal or intraaural, including administration as aqueous suspensions, oily preparations, etc. or as drops, sprays, suppositories, ointments, ointments, etc.; (c) administration via injection, subcutaneous, intraperitoneal, intravenous, intramuscular, intradermal, intraorbital, intracapsular, intraspinal, intrasternal, etc., including delivery by infusion pump; (d) topical administration, such as by direct injection into the kidney or heart area, for example, by implantation of a reservoir; and topical administration; as deemed appropriate by those skilled in the art, for contacting the compound of the present invention with living tissue.

[0298] The pharmaceutical composition suitable for administration includes a composition wherein the active ingredient is included in an amount that effectively achieves its intended purpose. The therapeutically effective amount of the compound disclosed herein required for the dosage will depend on the route of administration, the type of animal (including humans) being treated, and the physical characteristics of the particular animal being considered. The dosage can be customized to achieve the desired effect, but will depend on factors such as body weight, diet, simultaneous medication, and other factors that will be recognized by those skilled in the art. More specifically, a therapeutically effective amount means the amount of the compound that effectively prevents, alleviates, or improves the symptoms of the disease or prolongs the survival rate of the subject being treated. The determination of a therapeutically effective amount is fully within the capabilities of those skilled in the art, especially according to the detailed disclosure provided herein.

[0299] It will be apparent to those skilled in the art that useful in vivo dosages to be administered and specific modes of administration will vary according to age, body weight, and the mammalian species being treated, the specific compounds used, and the specific uses of these compounds. Those skilled in the art can use conventional pharmacological methods to determine effective dose levels, i.e., the dosage levels necessary to achieve the desired result. Typically, human clinical applications of the product begin with lower dosage levels, and dosage levels increase until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful dosages and routes of administration of compositions identified by this method using established pharmacological methods.

[0300] In non-human animal studies, the potential product is initially administered at a higher dose level and the dose is reduced until the desired effect is no longer achieved or the adverse side effects disappear. The dosage range can be very wide, depending on the desired effect and the therapeutic indication. Generally, the dosage can be between about 1 microgram / kg and 200 mg / kg body weight, preferably between about 180 microgram / kg and 10 mg / kg body weight. Alternatively, as will be appreciated by those skilled in the art, the dosage can be based on and calculated according to the patient's surface area.

[0301] The exact formulation, route of administration, and dosage of the pharmaceutical compositions of the present invention can be selected by the individual physician based on the patient's condition. (See, e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics," which is incorporated herein by reference in its entirety, with particular reference to Chapter 1, page 1). Typically, the dosage range of the composition administered to the patient can be about 0.5 to 1000 mg / kg of the patient's body weight. The dosage can be a single dose or a series of two or more doses given over the course of one or more days, depending on the patient's needs. Where human dosages for the compounds have been determined for at least some of the conditions, the present invention will use those same dosages, or dosages between about 0.1% and 500%, more preferably between about 25% and 250%, of the determined human dosages. Where no human dosage has been determined, as in the case of a newly discovered drug compound, a suitable human dosage can be derived from the ED 50 or TD 50 The values ​​may be extrapolated from in vitro or in vivo values, or other appropriate values ​​obtained, as defined by toxicity studies and efficacy studies in animals.

[0302] It should be noted that the attending physician will know how and when to terminate, interrupt or adjust administration due to toxicity or organ dysfunction. On the contrary, if the clinical response is insufficient (excluding toxicity), the attending physician will also know to adjust the treatment to a higher level. In the treatment of the obstacle being paid close attention to, the size of the administered dosage will vary with the severity of the condition to be treated and the route of administration. For example, the severity of the condition can be assessed in part by standard prognostic assessment methods. In addition, dosage and possible dosage frequency will also vary according to the age, weight and response of the individual patient. Programs comparable to those discussed above can be used in veterinary medicine.

[0303] Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations can be made about dosage. A daily dosage regimen for adult patients can be, for example, an oral dose of each active ingredient between 0.1 mg and 2000 mg, preferably between 1 mg and 500 mg, for example, 5 to 200 mg. In other embodiments, an intravenous, subcutaneous, or intramuscular dose of each active ingredient is between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, for example, 1 to 40 mg. In the case of administering a pharmaceutically acceptable salt, the dosage can be calculated as the free base. In some embodiments, the composition is administered 1 to 4 times a day. Alternatively, the composition of the present invention can be administered by continuous intravenous infusion, preferably at a dose of up to 1000 mg per day for each active ingredient. As will be appreciated by those skilled in the art, in some cases, it may be necessary to administer the compounds disclosed herein in an amount exceeding or even far exceeding the above-mentioned preferred dosage range in order to effectively and actively treat, in particular, invasive diseases or infections. In some embodiments, the compound is administered for a continuous therapy that lasts for a period of time, for example, for a week or longer, or for months or years.

[0304] In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, can be administered in the range of about 0.001 to about 1000 mg / kg body weight / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, can be administered in the range of about 0.5 to about 50 mg / kg / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (Iib), (Iic), (Iid), (III), (IV), or a pharmaceutically acceptable salt thereof, can be administered in the range of about 0.001 to about 7 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof may be administered in an amount of about 0.002 to about 6 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof may be administered in an amount of about 0.005 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof may be administered in an amount of about 0.01 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, may be administered in an amount of about 0.02 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, may be administered in an amount of about 0.05 to about 2.5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, may be administered in an amount of about 0.1 to about 1 g / day.In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be sufficient.

[0305] Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety sufficient to maintain the modulatory effect or minimum effective concentration (MEC). The MEC will vary for each compound but can be estimated based on in vitro data. The dosage required to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0306] Dosage intervals can also be determined using the MEC.The composition should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

[0307] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0308] The amount of composition administered may be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

[0309] The efficacy and toxicity of the compounds disclosed herein can be assessed using known methods. For example, the toxicology of a specific compound or a subset of compounds sharing certain chemical moieties can be determined by determining in vitro toxicity to a cell line (such as a mammal, preferably a human cell line). The results of such studies can generally predict the toxicity in an animal (such as a mammal, or more specifically, a human). Alternatively, the toxicity of a specific compound in an animal model (such as a mouse, rat, rabbit, or monkey) can be determined using known methods. The efficacy of a specific compound can be determined using several generally recognized methods, such as in vitro methods, animal models, or human clinical trials. There are generally recognized in vitro models for almost every type of disease, including but not limited to cancer, cardiovascular disease, and various immune dysfunctions. Similarly, acceptable animal models can be used to determine the efficacy of chemicals for treating such diseases. When selecting a model to determine efficacy, technicians can select appropriate models, dosages, routes of administration, and regimens under the guidance of the prior art. Of course, human clinical trials can also be used to determine the efficacy of a compound in the human body.

[0310] If desired, the composition may be present in a package or dispenser device that may contain one or more unit dosage forms containing the active ingredient. The package may, for example, comprise metal or plastic film, such as a blister pack. The package or dispenser device may be accompanied by instructions for use. The package or dispenser may also be accompanied by a notice associated with the container, the form of which is prescribed by a governmental agency governing the manufacture, use, or sale of pharmaceuticals, which reflects the agency's approval of the pharmaceutical form for human or veterinary use. For example, such a notice may be a prescription drug label approved by the U.S. Food and Drug Administration or an approved product package insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for use in treating a specified condition.

[0311] Administration and pharmaceutical compositions

[0312] Compound is applied with therapeutically effective dose.Although the human dosage level of compound as herein described has not yet been specifically determined, in general, daily dose can be about 0.25mg / kg to about 120mg / kg body weight or more, about 0.5mg / kg or less to about 70mg / kg body weight, about 1.0mg / kg to about 50mg / kg body weight or about 1.5mg / kg to about 10mg / kg body weight.Therefore, for the people being applied to 70kg body weight, dosage range will be about 17mg every day to about 8000mg every day, about 35mg every day or less to about 7000mg every day or more, about 70mg every day to about 6000mg every day, about 100mg every day to about 5000mg every day or about 200mg every day to about 3000mg.Certainly, the amount of the active compound applied will depend on the subject being treated and the disease state, the severity of the ailment, the mode of application and timetable and the judgment of the prescribing doctor.

[0313] The compounds disclosed herein, or pharmaceutically acceptable salts thereof, can be administered via any acceptable mode of administration of agents with similar uses, including but not limited to oral, subcutaneous, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular. Oral and parenteral administration are generally used to treat the indications that are the subject of the preferred embodiments.

[0314] The compounds useful as described above can be formulated into pharmaceutical compositions for treating these conditions. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st edition, Lippincott Williams & Wilkins (2005), which is incorporated by reference in its entirety. Thus, some embodiments include pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of a compound described herein (including enantiomers, diastereomers, tautomers, polymorphs, and solvates thereof) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof.

[0315] In addition to the useful selected compounds as described above, some embodiments also include compositions containing a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents, etc. The use of such media and medicaments for pharmaceutically active substances is well known in the art. Unless any conventional media or medicaments are incompatible with the active ingredient, their use in therapeutic compositions is considered. In addition, various adjuvants, such as adjuvants commonly used in the art, may be included. The considerations for including various components in pharmaceutical compositions are described in, for example, Gilman et al. (eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, which is incorporated herein by reference in its entirety.

[0316] Some examples of substances that can be used as pharmaceutically acceptable carriers or components thereof are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and methylcellulose; astragalus powder; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers such as TWEENS; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffered solution.

[0317] The choice of pharmaceutically acceptable carrier for use in conjunction with the subject compounds is essentially determined by the manner in which the compound is to be administered.

[0318] The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition containing a certain amount of compound, which is suitable for administration to animals, preferably mammalian subjects, in a single dose according to good medical practice. However, the preparation of a single dosage form or unit dosage form does not mean that the dosage form is administered once a day or once per course of treatment. It is expected that such dosage forms are administered once, twice, three times or more per day, and can be administered as an infusion over a period of time (e.g., about 30 minutes to about 2-6 hours), or as a continuous infusion, and can be given more than once during the course of treatment, although single administration is not particularly excluded. Technicians will recognize that formulations do not specifically consider the entire course of treatment, and such decisions are left to the technical staff of the therapeutic field rather than the formulation field.

[0319] Useful compositions as described above can be any of a variety of suitable forms for a variety of routes of administration, such as oral, nasal, rectal, topical (including transdermal), ophthalmic, intracerebral, intracranial, intrathecal, intraarterial, intravenous, intramuscular or other parenteral routes of administration. It will be appreciated by those skilled in the art that oral and nasal compositions include compositions administered by inhalation and prepared using available methods. Depending on the specific route of administration desired, various pharmaceutically acceptable carriers well known in the art can be used. Pharmaceutically acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropes, surfactants and encapsulating materials. Optional pharmaceutically active substances may be included that do not substantially interfere with the inhibitory activity of the compound. The amount of the carrier used in conjunction with the compound is sufficient to provide the actual amount of material for administration of the compound per unit dose. Techniques and compositions for preparing dosage forms useful in the methods described herein are described in the following references, all of which are incorporated herein by reference: Modern Pharmaceutics, 4th edition, Chapters 9 and 10 (Banker and Rhodes, eds., 2002); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms 8th edition (2004).

[0320] Various oral dosage forms can be used, including solid forms such as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet-milled, enteric-coated, sugar-coated, film-coated or multi-compressed, containing suitable binders, lubricants, diluents, disintegrants, colorants, flavorings, flow-inducing agents and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, melting agents, colorants and flavorings.

[0321] Pharmaceutically acceptable carriers suitable for preparing unit dosage forms for oral administration are well known in the art. Tablets typically contain conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose, and cellulose; binders, such as starch, gelatin, and sucrose; disintegrants, such as starch, alginic acid, and cross-linked carboxymethyl cellulose; and lubricants, such as magnesium stearate, stearic acid, and talc. Glidants, such as silicon dioxide, can be used to improve the flow characteristics of the powder mixture. Colorants, such as FD&C dyes, may be added for appearance. Sweeteners and flavorings, such as aspartame, saccharin, menthol, mint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically contain one or more of the solid diluents disclosed above. The choice of carrier component depends on secondary considerations, such as taste, cost, and shelf stability, which are not important and can be easily selected by those skilled in the art.

[0322] Oral compositions also include liquid solutions, emulsions, suspensions, and the like. Pharmaceutically acceptable carriers suitable for preparing such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions, and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol, and water. For suspensions, typical suspending agents include methylcellulose, sodium carboxymethylcellulose, AVICEL RC-591, tragacanth, and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methylparaben and sodium benzoate. Oral liquid compositions may also contain one or more components, such as the sweeteners, flavorings, and coloring agents disclosed above.

[0323] Such compositions may also be coated by conventional methods, typically using pH or time-dependent coatings, so that the subject compound is released in the gastrointestinal tract near the desired local application, or at different times to prolong the desired effect. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, ethylcellulose, Eudragit coatings, waxes, and shellac.

[0324] The compositions described herein may optionally include other pharmaceutically active substances.

[0325] Other compositions that can be used to achieve systemic delivery of the subject compounds include sublingual, oral, and nasal dosage forms. Such compositions typically contain one or more of the following: soluble filler materials such as sucrose, sorbitol, and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants, and flavorings disclosed above may also be included.

[0326] Liquid compositions formulated for topical ophthalmic use are formulated so that they can be topically applied to the eye. Comfort should be maximized as much as possible, although sometimes less than optimal comfort may be necessary for formulation considerations (e.g., drug stability). In cases where comfort cannot be maximized, liquids should be formulated so that patients can tolerate the liquid for topical ophthalmic use. Additionally, ophthalmologically acceptable liquids should be packaged for single use or contain preservatives to prevent contamination during multiple uses.

[0327] For ophthalmic applications, physiological saline solution is generally used as the primary vehicle to prepare solutions or medicines. Ophthalmic solutions should preferably be maintained at a suitable pH using an appropriate buffer system. The formulation may also contain conventional pharmaceutically acceptable preservatives, stabilizers, and surfactants.

[0328] Preservatives that can be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric, acetate, and phenylmercuric nitrate. A useful surfactant is, for example, Tween 80. Similarly, various useful vehicles can be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methylcellulose, poloxamer, carboxymethyl cellulose, hydroxyethyl cellulose, and purified water.

[0329] Tonicity adjusting agents may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol, and glycerol, or any other suitable ophthalmologically acceptable tonicity adjusting agent.

[0330] Various buffers and means of adjusting pH can be used, so long as the resulting formulation is ophthalmologically acceptable. For many compositions, the pH will be between 4 and 9. Thus, buffers include acetate buffers, citrate buffers, phosphate buffers, and borate buffers. Acids or bases can be used to adjust the pH of these formulations as needed.

[0331] Similarly, ophthalmically acceptable antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene.

[0332] Other excipient components that may be included in ophthalmic formulations are chelating agents. A useful chelating agent is disodium edetate, but other chelating agents may be used in place of or in combination with it.

[0333] For topical use, creams, ointments, gels, solutions or suspensions, etc. containing the compounds disclosed herein are used. Topical formulations can generally be composed of a pharmaceutical carrier, co-solvents, emulsifiers, penetration enhancers, preservative systems, and emollients.

[0334] For intravenous administration, the compounds and compositions described herein can be dissolved or dispersed in a pharmaceutically acceptable diluent, such as saline or glucose solution. Suitable excipients can be included to reach the required pH, including but not limited to NaOH, sodium carbonate, sodium acetate, HCl and citric acid. In various embodiments, the pH range of the final composition is 2 to 8, or preferably 4 to 7. Antioxidant excipients can include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea and EDTA. Other non-limiting examples of suitable excipients found in the final intravenous composition can include sodium phosphate or potassium phosphate, citric acid, tartaric acid, gelatin and carbohydrates such as dextrose, mannitol and dextran. Further acceptable excipients are described in Powell et al., Compendium of Excipients for Parenteral Formulations, PDA J Pharm Sci and Tech 1998, 52 238-311 and Nema et al., Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, PDA J Pharm Sci and Tech 2011, 65 287-332, both of which are incorporated herein by reference in their entirety. Antimicrobial agents may also be included to obtain bacteriostatic or fungistatic solutions, including but not limited to phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.

[0335] The composition for intravenous administration can be provided to the caregiver in the form of one or more solids, which are reconstituted with a suitable diluent such as sterile water, saline or glucose solution shortly before administration. In other embodiments, the composition is provided in the form of a solution for parenteral administration. In other embodiments, the composition is provided in the form of a solution further diluted before administration. In embodiments comprising the combination of a compound as herein described and another medicament, the combination can be provided to the caregiver as a mixture, or the caregiver can mix two medicaments before administration, or two medicaments can be administered separately.

[0336] The actual dosage of the active compounds described herein will depend on the specific compound and the condition to be treated; selection of the appropriate dosage is well within the knowledge of the skilled artisan.

[0337] Second (or other additional) agent

[0338] In some embodiments, the second therapeutic agent is an anti-inflammatory agent. In some embodiments, the second therapeutic agent is a nonsteroidal anti-inflammatory agent. In some embodiments, the second therapeutic agent is an anticancer agent.

[0339] In some embodiments, the method comprises administering an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV) or a pharmaceutically acceptable salt thereof in combination with an amount of a chemotherapeutic agent, wherein the combination and the amount of the chemotherapeutic agent together are effective to inhibit abnormal cell growth. Many chemotherapeutic agents are currently known in the art and can be used in combination. In some embodiments, the chemotherapeutic agent is selected from the group consisting of: a mitotic inhibitor, an alkylating agent, an antimetabolite, an intercalating antibiotic, a growth factor inhibitor, a cell cycle inhibitor, an enzyme, a topoisomerase inhibitor, a biological response modifier, an anti-hormone, an angiogenesis inhibitor, and an anti-androgen. Also described are methods for inhibiting abnormal cell growth in a mammal, comprising administering to the mammal an amount of a MEK protein kinase inhibitor and / or a Raf protein kinase inhibitor in combination with radiation therapy, wherein the amount of the MEK protein kinase inhibitor and / or the Raf protein kinase inhibitor combined with radiation therapy is effective to inhibit abnormal cell growth in the mammal or to treat a hyperproliferative disorder. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapies described herein.

[0340] In some embodiments, the present disclosure also relates to a method of inhibiting abnormal cell growth in a mammal, which may include a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), (IIc), (III), (IV) or a pharmaceutically acceptable salt thereof, and an amount of one or more substances selected from anti-angiogenic agents, signal transduction inhibitors, and anti-proliferative agents. Anti-angiogenic agents, such as MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors, can be used in combination with the compounds of the present invention and the pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96 / 33172 (published October 24, 1996), WO 96 / 27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98 / 07697 (published February 26, 1998), WO 98 / 03516 (published January 29, 1998), WO 98 / 34918 (published August 13, 1998), WO 98 / 34915 (published August 13, 1998), WO 98 / 33768 (published August 6, 1998), WO 98 / 30566 (published on July 16, 1998), European Patent Publication 606,046 (published on July 13, 1994), European Patent Publication 931,788 (published on July 28, 1999), WO 90 / 05719 (published on May 31, 1990), WO 99 / 52910 (published on October 21, 1999), WO 99 / 52889 (published on October 21, 1999), WO 99 / 29667 (published June 17, 1999), PCT International Application No. PCT / IB98 / 01113 (filed July 21, 1991), European Patent Application No. 99302232.1 (filed March 25, 1999), UK Patent Application No. 9912961.1 (filed June 3, 1999), U.S. Provisional Application No. 60 / 148,464 (filed August 12, 1999), U.S. Patent No. 5,863,949 (issued January 26, 1999), U.S. Patent No. 5,861,510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997).Some MMP-2 and MMP-9 inhibitors have little or no inhibitory activity against MMP-1, while some selectively inhibit MMP-2 and / or AMP-9 relative to other matrix metalloproteinases (e.g., MAP-1, NEMP-3, MMP-4, M7v1P-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, and MMP-13). Some specific examples of M1v1P inhibitors useful in the present invention are AG-3340, RU 32-3555, and RS 13-0830.

[0341] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IV), or a pharmaceutically acceptable salt thereof, is administered with at least one additional therapeutic agent. In some embodiments, the therapeutic agent is paclitaxel, bortezomib, or both. In further or additional embodiments, the therapeutic agent is selected from the group consisting of a cytotoxic agent, an anti-angiogenic agent, and an anti-tumor agent. In further or additional embodiments, the anti-tumor agent is selected from the group consisting of an alkylating agent, an antimetabolite, an epiphyllotoxin; an anti-tumor enzyme, a topoisomerase inhibitor, procarbazine, mitoxantrone, a platinum coordination complex, a biological response modifier and a growth inhibitor, a hormone / anti-hormonal therapeutic agent, and a hematopoietic growth factor.

[0342] Many chemotherapeutic agents are currently known in the art and can be used in combination with the compounds and compositions of the present disclosure. In some embodiments, the chemotherapeutic agent is selected from the group consisting of: mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.

[0343] In some embodiments, the combination is administered in combination with another therapy. In further or additional embodiments, the additional therapy is radiation therapy, chemotherapy, surgery, or any combination thereof. In further or additional embodiments, the combination is administered in combination with at least one additional therapeutic agent. In further or additional embodiments, the therapeutic agent is selected from the group consisting of a cytotoxic agent, an anti-angiogenic agent, and an anti-tumor agent. In further or additional embodiments, the anti-tumor agent is selected from the group consisting of an alkylating agent, an antimetabolite, an epipodophyllotoxin; an anti-tumor enzyme, a topoisomerase inhibitor, procarbazine, mitoxantrone, a platinum coordination complex, a biological response modifier and a growth inhibitor, a hormone / anti-hormonal therapeutic agent, and a hematopoietic growth factor.

[0344] In some embodiments, the second therapeutic agent is an agent for co-regulating the RAF pathway. In some embodiments, the second therapeutic agent is a RAF inhibitor. In one embodiment, the RAF inhibitor is vemurafenib, dabrafenib, conefantifenib, XL-281, LGX-818, CEP-32496, and ARQ-736.

[0345] In some embodiments, the second therapeutic agent is selected from aspirin; diflunisal; disalicylate; acetaminophen; ibuprofen; dexibuprofen; naproxen; fenoprofen; ketoprofen; dexketoprofen; flurbiprofen; oxaprozin; cloxoprofen; indomethacin; tolmetin; sulindac; etodolac; ketorolac; diclofenac; aceclofenac; nabumetone; enolic acid; piroxicam; meloxicam; tenoxicam; droxicam; lornoxicam; isoxicam; mefenamic acid; meclofenamic acid; flufenamic acid; tolfenamic acid; sulfonanilides; clonixin; levofloxacin; dexamethasone; and prednisone.

[0346] In some embodiments, the second therapeutic agent is selected from mechlorethamine; cyclophosphamide; melphalan; chlorambucil; ifosfamide; busulfan; N-nitroso-N-methylurea (MNU); carmustine (BCNU); lomustine (CCNU); semustine (MeCCNU); fotemustine; streptozotocin; dacarbazine; mitozolomide; temozolomide; thiotepa; azithromycin; diazocone (AZQ); cisplatin; carboplatin; and oxaliplatin.

[0347] In some embodiments, the second therapeutic agent is selected from vincristine; vinblastine; vinorelbine; vindesine; vinflunine; paclitaxel; docetaxel; etoposide; teniposide; tofacitinib; ixabepilone; irinotecan; topotecan; camptothecin; doxorubicin; mitoxantrone; and teniposide.

[0348] In some embodiments, the second therapeutic agent is selected from dactinomycin; bleomycin; plicamycin; mitomycin; daunorubicin; epirubicin; idarubicin; pirarubicin; aclarubicin; mitoxantrone; cyclophosphamide; methotrexate; 5-fluorouracil; prednisolone; folinic acid; methotrexate; melphalan; capecitabine; mechlorethamine; uracil; melphalan; chlorambucil; ifosfamide; bendamustine; 6-mercaptopurine; and procarbazine.

[0349] In some embodiments, the second therapeutic agent is selected from cladribine; pemetrexed; fludarabine; gemcitabine; hydroxyurea; nelarabine; cladribine; clofarabine; cytarabine; decitabine; cytarabine; liposomal cytarabine; pralatrexate; floxuridine; fludarabine; colchicine; thioguanine; cabazitaxel; larotaxel; ortataxel; tesetaxel; aminopterin; pemetrexed; pralatrexate; raltitrexed; pemetrexed; carmofur; and floxuridine.

[0350] In some embodiments, the second therapeutic agent is selected from azacitidine; decitabine; hydroxyurea; topotecan; irinotecan; belotecan; teniposide; aclarubicin; epirubicin; idarubicin; amrubicin; pirarubicin; valrubicin; doxycycline; mitoxantrone; pixantrone; mechlorethamine; chlorambucil; prednimustine; uramustine; estramustine; carmustine; lomustine; fotemustine; nimustine; ranimustine; carboquone; thiotepa; triazinon; and triethylene melamine.

[0351] In some embodiments, the second therapeutic agent is selected from nedaplatin; sitaplatin; procarbazine; dacarbazine; temozolomide; hexamethylmelamine; dibromomannitol; pipobroman; actinomycin; bleomycin; plicamycin; aminopyruvic acid; methyl aminolevulinate; iproxicam; talaporfin; temoporfin; verteporfin; avosidic acid; cericlib; palbociclib; bortezomib; carfilzomib; anagrelide; masoprofen; olaparib; belinostat; panobinostat; romidepsin; vorinostat; idelalisib; atrasentan; bexarotene; testolactone; amsacrine; trabectedin; alitretinoin; tretinoin; colcemid; elsamitrucin; etoglucagon; lonidamine; lucanthone; mitoguanzone; mitotane; oblimersen; homoharringtonine; and eribulin.

[0352] In some embodiments, the second therapeutic agent is selected from azathioprine; mycophenolic acid; leflunomide; teriflunomide; tacrolimus; cyclosporine; pimecrolimus; abetimus; gustation; lenalidomide; pomalidomide; thalidomide; anakinra; sirolimus; everolimus; temsirolimus; umimios; zotarolimus; eculizumab; adalimumab; afelimumab; peg-sporin; Tocilizumab; golimumab; infliximab; neritumumab; mepolizumab; omalizumab; faramomab; icitumomab; neritumumab; ustekinumab; etanercept; otelizumab; teplizumab; visilizumab; cleximab; keliximab; zalimumab; efalizumab; erlizumab; obinutuzumab; rituximab; and orelizumab.

[0353] In some embodiments, the second therapeutic agent is selected from the group consisting of pascolizumab; gomilimab; ruximab; tenecteixumab; tocilizumab; aseluzumab; galiximab; gavilimumab; lulizumab; belimumab; bilimud; ipilimumab; tremelimumab; betilimumab; lerdetumumab; metilimumab; natalizumab; tocilizumab; odulumumab; basiliximab ; daclizumab; inomucosumab; atozololumab; atumumab; cilizumab; fontuzumab; masitumomab; murolimumab; pexelizumab; reslizumab; rovizumab; ciplizumab; talizumab; atemutuzumab; valiximab; vepamomab; abatacept; belatacept; penetracept; aflibercept; afacept; and rilonacept.

[0354] Therefore, some aspects described herein involve the following numbered alternatives:

[0355] 1. A compound having a structure of formula (III):

[0356]

[0357] Including pharmaceutically acceptable salts thereof, wherein:

[0358] R 2 、R 6 、R 7 and R 13 each independently selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0359] R 3 is chlorine, bromine or iodine;

[0360] X is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0361] Y is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0362] L is –Z1-Z2 or –Z1-Z2-Z3;

[0363] Z1, Z2 and Z3 are independently selected from the group consisting of: –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and

[0364] Each R 5 and R 5′ independently selected from H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group and optionally substituted C3 to C 10 Heteroaryl.

[0365] 2. The compound according to alternative 1, wherein R 6 is H, deuterium, hydroxyl or halogenated.

[0366] 3. A compound according to alternative 1 or 2, wherein R 6 is H or halogenated.

[0367] 4. A compound according to any one of alternatives 1 to 3, wherein halo is selected from fluoro, chloro or bromo.

[0368] 5. A compound according to any one of alternatives 1 to 4, wherein R 7 For L.

[0369] 6. The compound according to Alternative Scheme 5, wherein L is -Z1-Z2.

[0370] 7. The compound according to Alternative Scheme 6, wherein Z1 is -CH2-.

[0371] 8. A compound according to alternative 6 or 7, wherein Z2 is selected from optionally substituted C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, -NR 5 R 5 ', –CH2CCH or –CH2CN.

[0372] 9. The compound according to Alternative Scheme 5, wherein L is -Z1-Z2-Z3.

[0373] 10. The compound according to alternative 9, wherein Z1 is -CH2-, and Z2 is selected from the group consisting of: -NR 5 R 5’, -NHCH2CO-, C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, and Z3 is selected from the group consisting of H, deuterium, halo, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl or -CH2-(optionally substituted aryl).

[0374] 11. A compound according to any one of alternatives 1 to 10, wherein R 3 For chlorine.

[0375] 12. A compound according to any one of alternatives 1 to 10, wherein R 3 For bromine.

[0376] 13. A compound according to any one of Alternatives 1 to 10, wherein R 3 For iodine.

[0377] 14. A compound according to any one of Alternatives 1 to 13, wherein R 2 For L.

[0378] 15. The compound according to Alternative 14, wherein L is -Z1-Z2.

[0379] 16. The compound according to Alternative 15, wherein Z1 is -CH2- or -NH-.

[0380] 17. A compound according to any one of alternatives 1 to 16, wherein X is CH2 or

[0381] 18. A compound according to any one of Alternatives 1 to 17, wherein Y is CH2 or

[0382] 19. The compound according to Alternative 1, wherein the compound is selected from the compounds of Table B, C, D or E.

[0383] 20. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound having the structure of formula (III)

[0384]

[0385] Including pharmaceutically acceptable salts thereof, wherein:

[0386] R 2 、R 6 、R 7 and R 13each independently selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0387] R 3 is chlorine, bromine or iodine;

[0388] X is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0389] Y is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0390] L is –Z1-Z2 or –Z1-Z2-Z3;

[0391] Z1, Z2 and Z3 are independently selected from the group consisting of: –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and

[0392] Each R 5 and R 5′ independently selected from H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group and optionally substituted C3 to C 10 Heteroaryl.

[0393] 21. The pharmaceutical composition according to alternative 20, wherein R 6 is H, deuterium, hydroxyl or halogenated.

[0394] 22. The pharmaceutical composition according to alternative 20 or 21, wherein R 6 is H or halogenated.

[0395] 23. The pharmaceutical composition of any one of Alternatives 20 to 22, wherein halo is selected from chloro or bromo.

[0396] 24. A pharmaceutical composition according to any one of Alternatives 20 to 23, wherein R 7 For L.

[0397] 25. The pharmaceutical composition of Alternative 24, wherein L is -Z1-Z2.

[0398] 26. The pharmaceutical composition of Alternative 25, wherein Z1 is -CH2-.

[0399] 27. The pharmaceutical composition of alternative 25 or 26, wherein Z2 is selected from optionally substituted C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, -NR 5 R 5 ', –CH2CCH or –CH2CN.

[0400] 28. The pharmaceutical composition of Alternative 24, wherein L is -Z1-Z2-Z3.

[0401] 29. The pharmaceutical composition of Alternative 28, wherein Z1 is -CH2-, and Z2 is selected from the group consisting of: -NR 5 R 5’ , -NHCH2CO-, C3 to C8 cycloalkyl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 heteroaryl, and Z3 is selected from the group consisting of H, deuterium, halo, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl or -CH2-(optionally substituted aryl).

[0402] 30. The pharmaceutical composition of any one of Alternatives 20 to 29, wherein R 3 For chlorine.

[0403] 31. A pharmaceutical composition according to any one of Alternatives 20 to 29, wherein R 3 For bromine.

[0404] 32. A pharmaceutical composition according to any one of Alternatives 20 to 29, wherein R 3 For iodine.

[0405] 33. A pharmaceutical composition according to any one of Alternatives 30 to 32, wherein R 13 For L.

[0406] 34. The pharmaceutical composition of Alternative 33, wherein L is -Z1-Z2.

[0407] 35. The pharmaceutical composition of Alternative 34, wherein Z1 is -CH2- or -NH-.

[0408] 36. A pharmaceutical composition according to any one of Alternatives 20 to 35, wherein X is CH2 or

[0409] 37. A pharmaceutical composition according to any one of Alternatives 20 to 36, wherein Y is CH2 or

[0410] 38. The pharmaceutical composition of Alternative 20, wherein the compound is selected from the compounds of Table B, C, D or E.

[0411] 39. The pharmaceutical composition of any one of Alternatives 20 to 38, further comprising one or more immune checkpoint inhibitors.

[0412] 40. The pharmaceutical composition of Alternative 40, wherein the immune checkpoint inhibitor is an inhibitor of PD-1, PD-L1, PD-L2, PD-L3, PD-L4, CTLA-4, LAG3, B7-H3, B7-H4, KIR or TIM3.

[0413] 41. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-1 inhibitor.

[0414] 42. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.

[0415] 43. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-L2 inhibitor.

[0416] 44. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0417] 45. The pharmaceutical composition of Alternative 39 or 40 comprising a first immune checkpoint inhibitor and a second immune checkpoint inhibitor, wherein the first immune checkpoint inhibitor is different from the second immune checkpoint inhibitor.

[0418] 46. ​​The pharmaceutical composition of Alternative Embodiment 39 or 40, wherein the first immune checkpoint inhibitor and the second immune checkpoint inhibitor are independently inhibitors of PD-1, PD-L1, PD-L2, PD-L3, PD-L4, CTLA-4, LAG3, B7-H3, B7-H4, KIR or TIM3.

[0419] 47. The pharmaceutical composition of Alternative 39 or 40, wherein the first immune checkpoint inhibitor is a PD-1 inhibitor and the second immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0420] 48. The pharmaceutical composition of Alternative 39 or 40, wherein the first immune checkpoint inhibitor is a PD-L1 inhibitor and the second immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0421] 49. The pharmaceutical composition of Alternative 39 or 40, wherein the first immune checkpoint inhibitor is a PD-L2 inhibitor and the second immune checkpoint inhibitor is a CTLA-4 inhibitor.

[0422] 50. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is an antibody.

[0423] 51. The pharmaceutical composition of alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-1 antibody.

[0424] 52. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-L1 antibody.

[0425] 53. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is a PD-L2 antibody.

[0426] 54. The pharmaceutical composition of alternative 39 or 40, wherein the immune checkpoint inhibitor is a CTLA-4 antibody.

[0427] 55. The pharmaceutical composition of Alternative 39 or 40, wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, ipilimumab, BMS 936559, atezolizumab, durvalumab, or any combination thereof.

[0428] 56. A method of treating a mammal suffering from a disease or disorder, said method comprising administering to said mammal a therapeutically effective amount of a compound according to any one of Alternatives 1 to 19 or a pharmaceutical composition according to any one of Alternatives 20 to 55.

[0429] 57. A method of treating a disease or disorder, said method comprising administering to a subject suffering from said disease or disorder an effective amount of a compound according to any one of Alternatives 1 to 19 or a pharmaceutical composition according to any one of Alternatives 20 to 55.

[0430] 58. A method of treating a disease, said method comprising administering to a subject suffering from said disease an effective amount of a compound according to any one of Alternatives 1 to 19 or a pharmaceutical composition according to any one of Alternatives 20 to 55.

[0431] 59. The method of any one of Alternatives 56 to 58, wherein the disease is cancer.

[0432] 60. A method of treating cancer cachexia in a mammal having cancer, said method comprising administering an effective amount of a compound according to any one of Alternatives 1 to 19 or a pharmaceutical composition according to any one of Alternatives 20 to 55.

[0433] 61. The method of any one of Alternatives 56 to 60, wherein the compound of any one of Alternatives 1 to 19 or the pharmaceutical composition of any one of Alternatives 20 to 55.

[0434] 62. The method of any one of Alternatives 56 to 60, wherein the compound of any one of Alternatives 1 to 19 or the pharmaceutical composition of any one of Alternatives 20 to 55.

[0435] 63. The method of any one of Alternatives 56 to 60, wherein the compound of any one of Alternatives 1 to 19 or the pharmaceutical composition of any one of Alternatives 20 to 55 is administered in multiple doses, more than once per day.

[0436] 64. The method of Alternative 59 wherein the cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, stomach cancer, prostate cancer, kidney cancer, colorectal cancer, or leukemia. In further or additional embodiments, the fibrogenic disorder is scleroderma, polymyositis, systemic lupus erythematosus, rheumatoid arthritis, cirrhosis of the liver, keloid formation, interstitial nephritis, or pulmonary fibrosis.

[0437] 65. The method of Alternative 59 or 64, wherein the cancer is associated with a RAS mutation.

[0438] 66. The method of alternative 65, wherein the RAS mutation is a KRAS mutation selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R and Q61H.

[0439] 67. A compound having a chemical structure of formula (IV)

[0440]

[0441] or a pharmaceutically acceptable salt thereof, wherein:

[0442] R6 is hydrogen, fluorine or chlorine;

[0443] R 13 Ethyl or -NR A R B , where R A is hydrogen and R B is methyl;

[0444] Z2 is -NR 5 R 5’ 、 R 5 is a C1 to C6 alkyl group; and

[0445] R 5’ It is a C1 to C6 alkyl group.

[0446] 68. A compound according to alternative 67, wherein R 5 It is a methyl group.

[0447] 69. A compound according to alternative 68, wherein R 5 ' is a methyl group.

[0448] 70. A compound according to alternative 68, wherein R 5 ' is ethyl.

[0449] 71. A compound according to any one of Alternatives 67 to 70, wherein Z2 is -NR 5 R 5’ .

[0450] 72. A compound according to any one of Alternatives 67 to 71, wherein R 13 -NR A R B .

[0451] 73. The compound according to Alternative 72, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0452] 74. The compound according to Alternative 72, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0453] 75. The compound according to Alternative 72, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0454] 76. The compound according to Alternative 72 wherein the compound is or a pharmaceutically acceptable salt thereof.

[0455] 77. The compound according to Alternative 72, wherein the compound is or, or a pharmaceutically acceptable salt thereof.

[0456] 78. The compound according to Alternative 72, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0457] 79. A compound according to any one of Alternatives 67 to 71, wherein R 13 For ethyl.

[0458] 80. The compound according to Alternative 79, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0459] 81. The compound according to Alternative 79, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0460] 82. The compound according to Alternative 79, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0461] 83 A compound according to any one of Alternatives 67 to 70, wherein Z2 is

[0462] 84. A compound according to alternative 83, wherein R 13 For ethyl.

[0463] 85. The compound according to alternative 84, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0464] 86. The compound according to alternative 84, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0465] 87. The compound according to Alternative 84, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0466] 88. A compound according to alternative 83, wherein R 13 -NR A R B .

[0467] 89. The compound according to Alternative 88, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0468] 90. The compound according to Alternative 88, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0469] 91. The compound according to Alternative 88, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0470] 92. A compound according to any one of Alternatives 67 to 70, wherein Z2 is

[0471]

[0472] 93. A compound according to alternative 92, wherein R 13 For ethyl.

[0473] 94. A compound according to alternative 92, wherein R 13 -NR A R B .

[0474] 95. The compound according to alternative 92 or 94, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0475] 96. The compound according to alternative 92 or 94, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0476] 97. The compound according to alternative 92 or 94, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0477] 98. A compound having a structure of formula (III):

[0478]

[0479] Including pharmaceutically acceptable salts thereof, wherein:

[0480] R 2 is L;

[0481] R 6 Selected from the group consisting of H or fluorine, chlorine or bromine;

[0482] R 7 is H;

[0483] R 13 and optionally substituted amine, C1 to C6 alkyl, H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0484] R 3 For chlorine;

[0485] X is –O–;

[0486] Y is

[0487] L is –Z1-Z2;

[0488] Z1 is –CH2–; and

[0489] Z2 is selected from the group consisting of: –NR 5 R 5′ , optionally substituted C3 to C8 heterocyclyl, –CH2–, –O–, –S–, S═O, –SO2–, C═O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 Aryl, optionally substituted C3 to C 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and

[0490] Each R 5 and R 5′ Independently selected from optionally substituted C1 to C6 alkyl.

[0491] 99. The compound according to alternative 98, wherein Z2 is -NR 5 R 5′ .

[0492] 100. The compound according to alternative 99, wherein R 5 It is a methyl group.

[0493] 101. A compound according to alternative 99, wherein R 5 ' is a methyl group.

[0494] 102. The compound according to alternative 99, wherein R 5 ' is ethyl.

[0495] 103. A compound according to alternative 98, wherein Z2 is

[0496] 104. A compound according to Alternative Scheme 98, wherein Z2 is optionally substituted Where n is 1, 2, 3 or 4.

[0497] 105. The compound according to Alternative 104, wherein n is 1.

[0498] 106. A compound according to any one of Alternatives 98 to 105, wherein R 13 -NR A R B , where R A and R B Each independently selected from hydrogen or C 1-6 alkyl.

[0499] 107. A compound according to alternative 106, wherein R A is hydrogen and R B It is a methyl group.

[0500] 108. A compound according to any one of Alternatives 98 to 105, wherein R 13 It is a C1 to C6 alkyl group.

[0501] 109. The compound according to alternative 108, wherein R 13 For ethyl.

[0502] 110. A compound according to any one of Alternatives 98 to 109, wherein R 6 For fluorine.

[0503] 111. A compound according to any one of Alternatives 98 to 109, wherein R 6 For chlorine.

[0504] 112. A compound according to any one of Alternatives 98 to 109, wherein R 6 For H.

[0505] 113. A compound having a structure of formula (III):

[0506]

[0507] Including pharmaceutically acceptable salts thereof, wherein

[0508] R 2 is L;

[0509] R 6 Selected from the group consisting of H or fluorine, chlorine or bromine;

[0510] R 7 is H;

[0511] R 13 is a C1 to C6 alkyl group;

[0512] R 3 For chlorine;

[0513] X is –O–;

[0514] Y is

[0515] L is –Z1-Z2;

[0516] Z1 is –CH2–;

[0517] Z2 is –NR 5 R 5′ ;as well as

[0518] Each R 5 and R 5′ Independently selected from optionally substituted C1 to C6 alkyl.

[0519] 114. A compound having a structure of formula (III):

[0520]

[0521] Including pharmaceutically acceptable salts thereof, wherein

[0522] R 2 and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0523] R 6and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, alkylamino, 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0524] R 7 and optionally substituted alkyl, alkyl, alkyl, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, alkylene, 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0525] R 13and optionally substituted C1 to C6 alkyl, optionally substituted amino, H, deuterium, hydroxy, halogen, cyano, nitro, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0526] R 3 is chlorine, bromine or iodine;

[0527] X is –O–, C(R 5 )2、CH(R 5 ), CH2,

[0528] Y is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0529] L is –Z1-Z2 or –Z1-Z2-Z3;

[0530] Z1 is selected from the group consisting of: –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl);

[0531] Z2 is selected from the group consisting of: –NR 5 R 5′ , –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5–, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl);

[0532] Z3 is selected from the group consisting of: –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5–, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and

[0533] Each R 5 and R 5′ independently selected from optionally substituted C1 to C6 alkyl, H, deuterium, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group and optionally substituted C3 to C 10 Heteroaryl.

[0534] 115. A compound selected from the list consisting of:

[0535]

[0536]

[0537] 116. A compound selected from the list consisting of:

[0538]

[0539]

[0540] 117. A pharmaceutical composition comprising a compound according to any one of Alternatives 67 to 116, or a pharmaceutically acceptable salt thereof.

[0541] 118. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound according to any one of Alternatives 67 to 116, or a pharmaceutical composition thereof.

[0542] 119. Use of a compound according to any one of Alternatives 67 to 116 for the treatment of cancer.

[0543] 120. A compound selected from the group consisting of:

[0544] 4-((Dimethylamino)methyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0545] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0546] 4-((dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methyl

[0547] -2-oxo-2H-chromen-7-yldimethylcarbamate; and

[0548] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0549] 121. A compound according to Alternative 120 wherein the compound is 4-((dimethylamino)methyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0550] 122. A compound according to Alternative 120 wherein the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methyl-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0551] 123. A compound according to Alternative 120 wherein the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0552] 124. A pharmaceutical composition comprising a compound according to Alternative 1 and a pharmaceutically acceptable salt.

[0553] 125. A compound selected from the group consisting of:

[0554] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0555] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0556] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0557] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0558] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0559] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0560] 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0561] 6-chloro-3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate;

[0562] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate; and

[0563] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo

[0564] -2H-chromen-7-yl dimethylcarbamate.

[0565] 126. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0566] 127. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate.

[0567] 128. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0568] 129. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate.

[0569] 130. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate.

[0570] 131. A compound according to Alternative 126 wherein the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate.

[0571] 132. A compound according to Alternative 126 wherein the compound is 6-chloro-3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate.

[0572] 133. A compound according to Alternative 126, wherein the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate.

[0573] 134. A compound according to Alternative 126 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0574] 135. A pharmaceutical composition comprising a compound according to any one of Alternatives 126 to 134 and a pharmaceutically acceptable salt

[0575] 136. A compound selected from the group consisting of:

[0576] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-6-fluoro

[0577] -2-oxo-2H-chromen-7-yldimethylcarbamate;

[0578] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo

[0579] -2H-chromen-7-yl dimethylcarbamate;

[0580] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0581] 4-(azetidin-1-ylmethyl)-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0582] 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0583] 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate; and

[0584] 4-(azetidin-1-ylmethyl)-6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0585] 137. A compound according to Alternative 136 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0586] 138. A compound according to Alternative 136 wherein the compound is 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0587] 139. A compound according to Alternative 136 wherein the compound is 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0588] 140. A compound according to Alternative 136 wherein the compound is 4-(azetidin-1-ylmethyl)-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0589] 141. A compound according to Alternative 136 wherein the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0590] 142. A compound according to Alternative 136 wherein the compound is 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0591] 143. A pharmaceutical composition comprising a compound according to any one of Alternatives 136 to 142 and a pharmaceutically acceptable salt.

[0592] 144. A compound selected from the group consisting of:

[0593] 3-(2-Fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0594] 3-(3-(ethylsulfonamido)-2-fluorobenzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0595] 3-(2-Fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-((methyl(prop-2-yn-1-yl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0596] 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0597] 4-(((CyanomethyI)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0598] 4-((dimethylamino)methyl)-3-(2-fluoro-3-(methyl(sulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0599] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0600] 4-((dimethylamino)methyl)-3-(3-((ethylsulfonyl)methyl)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate; and

[0601] 3-(3-((tert-Butylsulfinyl)amino)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0602] 145. A compound according to Alternative 144 wherein the compound is 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0603] 146. The compound of Alternative 144, wherein the compound is 3-(3-(ethylsulfonamido)-2-fluorobenzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate;

[0604] 147. A compound according to Alternative 144, wherein the compound is 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-((methyl(prop-2-yn-1-yl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0605] 148. A compound according to Alternative 144 wherein the compound is 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0606] 149. A compound according to Alternative 144 wherein the compound is 4-(((cyanomethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0607] 150. A compound according to Alternative 144 wherein the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-(methyl(sulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0608] 151. A compound according to Alternative 144 wherein the compound is 4-((dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0609] 152. A compound according to Alternative 144 wherein the compound is 3-(3-((tert-butylsulfinyl)amino)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate.

[0610] 153. A pharmaceutical composition comprising a compound according to any one of Alternatives 144 to 152 and a pharmaceutically acceptable salt.

[0611] 154. A compound having a structure of formula (III):

[0612]

[0613] including pharmaceutically acceptable salts thereof,

[0614] in,

[0615] R 2 、R 6 、R7 and R 13 each independently selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl and L;

[0616] R 3 For chlorine;

[0617] X is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0618] Y is C(R 5 )2、CH(R 5 ), CH2, –O–,

[0619] L is –Z1-Z2 or –Z1-Z2-Z3;

[0620] Z1, Z2 and Z3 are independently selected from the group consisting of: –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5NH–,–R 5 NH(CO)–,–R 5 (CO)NH–、–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 ,–SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –,–(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and

[0621] Each R 5 and R 5′ independently selected from H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclic group and optionally substituted C3 to C 10 Heteroaryl.

[0622] 155. A compound or pharmaceutically acceptable salt according to Alternative 154, wherein R 2 It is CH2-Z2.

[0623] 156. A compound or pharmaceutically acceptable salt according to Alternative 155, wherein Z2 is -NR 5 R 5’ or an optionally substituted C3 to C8 heterocyclyl.

[0624] 157. A compound or pharmaceutically acceptable salt according to Alternative 155 or Alternative 156, wherein Z2 is -NR 5 R5 'And R 5 and R 5 ' is each an optionally substituted C1 to C6 alkyl group, optionally wherein R 5 and R 5 'Each is Me, optionally wherein R 5 for Me and R 5 'For Et.

[0625] 158. A compound or pharmaceutically acceptable salt according to Alternative 155 or Alternative 156 wherein Z2 is an optionally substituted C3 to C8 heterocyclyl and the heterocycle is a nitrogen-containing heterocyclyl, optionally wherein Z2 is

[0626] 159. A compound or pharmaceutically acceptable salt according to any one of Alternatives 154 to 158, wherein Y is CH2 or

[0627] 160. The compound or pharmaceutically acceptable salt according to Alternative 159, wherein Y is

[0628] 161. A compound or pharmaceutically acceptable salt according to any one of Alternatives 154 to 160, wherein R 6 is H or halo, optionally wherein halo is selected from fluoro, chloro or bromo, optionally wherein halo is fluoro or chloro, optionally wherein halo is chloro.

[0629] 162. A compound or pharmaceutically acceptable salt according to any one of Alternatives 154 to 161, wherein R 7 For H.

[0630] 163. A compound or pharmaceutically acceptable salt according to any one of Alternatives 154 to 162 wherein X is O.

[0631] 164. A compound or pharmaceutically acceptable salt according to any one of Alternatives 154 to 163, wherein R 13 is an optionally substituted amino group or an optionally substituted C1 to C6 alkyl group.

[0632] 165. A compound or pharmaceutically acceptable salt according to any one of Alternative 164, wherein R 13 is NHMe or Et, optionally wherein R 13 For NHMe.

[0633] 166. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is selected from the group consisting of:

[0634]

[0635]

[0636] as well as

[0637]

[0638] 167. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0639]

[0640] 168. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0641]

[0642] 169. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0643]

[0644] 170. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0645]

[0646] 171. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0647]

[0648] 172. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0649]

[0650] 173. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0651]

[0652] 174. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0653]

[0654] 175. The compound or pharmaceutically acceptable salt of Alternative 154, wherein the compound is:

[0655]

[0656] 176. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined in any one of Alternatives 154 to 175, or a pharmaceutically acceptable salt thereof.

[0657] 177. A compound as defined in any one of Alternatives 154 to 175, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

[0658] Examples

[0659] General Procedures

[0660] Additional embodiments are disclosed in further detail in the following examples, which are not intended in any way to limit the scope of the claims.

[0661] The materials used to prepare the compounds of Formula (I), (Ia), (Ib), or (Ic) described herein can be prepared by known methods or are commercially available. In these reactions, variations known to those of ordinary skill in the art but not mentioned in greater detail may also be used. The skilled artisan, having access to the literature and this disclosure, is fully capable of preparing any of the compounds.

[0662] It will be appreciated that those skilled in the art of organic chemistry can readily perform the operations without further instruction, that is, it is well within the skill and practice to perform these operations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, electrophilic and nucleophilic aromatic substitutions, etherifications, esterifications, and saponifications. These operations are discussed in standard textbooks such as March's Advanced Organic Chemistry (Wiley), Carey and Sundberg, Advanced Organic Chemistry (incorporated herein by reference in its entirety), and the like.

[0663] It will be readily understood by the skilled person that certain reactions are best carried out when other functional groups in the molecule are masked or protected, thereby avoiding any undesirable side reactions and / or increasing the yield of the reaction. The skilled person typically utilizes protecting groups to achieve this increased yield or to avoid undesirable reactions. These reactions can be found in the literature and are also fully within the skill's scope. Examples of many of these operations can be found in, for example, T. Greene and P. Wuts Protecting Groups in Organic Synthesis, 4th edition, John Wiley & Sons (2007), which is incorporated herein by reference in its entirety.

[0664] The following example schemes are provided to guide the reader and represent preferred methods for preparing the compounds exemplified herein. These methods are not restrictive, and it is apparent that other approaches can be used to prepare these compounds. Such methods specifically include solid-phase-based chemistry, including combinatorial chemistry. The skilled person is fully capable of preparing these compounds by those methods provided in the literature and this disclosure. The compound numbers used in the synthetic schemes described below refer only to those specific schemes and should not be interpreted as or confused with the same numbers in other parts of the application.

[0665] The trademarks used herein are examples only and reflect the illustrative material used in connection with the present invention. A skilled artisan will recognize that variations in batches, manufacturing processes, etc. are to be expected. Thus, the examples and the trademarks used therein are non-limiting and are not intended to be limiting, but merely illustrative of how a skilled artisan may choose to implement one or more embodiments of the present invention.

[0666] The following example schemes are provided for guidance of the reader and collectively represent example methods for preparing the compounds provided herein. In addition, other methods for preparing the compounds described herein will be apparent to those of ordinary skill in the art based on the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.

[0667] Example 1

[0668] General Synthesis A

[0669]

[0670] Compound 2: To a solution of compound 1 and NBS (57.8 g, 321 mmol, 1.20 equiv) in MeCN (1340 mL) was added 1,1-azobis(cyclohexanecarbonitrile) (0.12 equiv) under a nitrogen atmosphere. The resulting reaction mixture was stirred at 80 ° C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give an orange suspension. Et2O was added and the resulting suspension was stirred at room temperature for 18 hours. The suspension was filtered and the residue was washed with some additional Et2O. The combined organic layers were washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give benzyl bromide compound 2 as a dark red oil that crystallized after standing.

[0671] Compound 3: A mixture of compound 2 (1.0 equivalents) and sodium iodide (1.0 equivalents) was stirred in THF (dry) for 30 min. In another flask, ethyl 3-oxobutanoate (1.10 equivalents) was dissolved in THF (dry) and lithium tert-butoxide (1.10 equivalents) was slowly added. The reaction mixture was stirred for 30 min and then slowly added to the bromide suspension. The resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water, and the product was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a dark brown oil. The oil was applied to a water matrix and purified by column chromatography using method "flash distillation" (heptane / EtOAc=1:0→7:3) to obtain compound 3, which was a light yellow oil.

[0672] Compound 4: To a solution of compound 3 (1.0 equiv) in perchloric acid or methanesulfonic acid (10-20 equiv) was added a resorcinol derivative (1.2 equiv). The reaction mixture was stirred at room temperature for 1–18 h. Water was added to the reaction mixture, and the product was filtered and washed with water and Et2O. The residue was dried to afford coumarin compound 4 as a solid.

[0673] Compound 5: To a solution of compound 4 (1.0 equiv) in DMF (dry) (0.1–0.2 M) at 0°C under N2 atmosphere was added a 60% dispersion of sodium hydride in mineral oil (1.60 equiv). The reaction mixture was stirred for 10 min, then dimethylcarbamoyl chloride (1.50–1.60 equiv) was added. The reaction mixture was warmed to room temperature and stirred for an additional 2–60 h. Water was added to quench the reaction mixture. The suspension was filtered and washed with water and Et2O. The residue was dried to afford the dimethylcarbamate compound 5 as a solid.

[0674] Compound 5: Dimethylcarbamate (1.0 eq) was suspended in methanol (0.2 M) and some CH2Cl2 was added to give a solution. Argon was bubbled through the solution for 10 min. Then 50% A nickel slurry (1.0 equiv) or 10% palladium on activated carbon (0.05 equiv) was added. The resulting reaction mixture was purged with hydrogen and stirred at room temperature for 2–18 h. The reaction mixture was filtered through celite and washed with MeCN, CH2Cl2, and MeOH. The filtrate was concentrated under reduced pressure to provide the primary amine as a solid.

[0675] Compound 7: To an ice-bath cooled (0°C) suspension of aniline compound 6 (1.0 equiv) and pyridine (3.0 equiv) in DMF (0.2 M) was added dropwise a solution of methylsulfamoyl chloride (2.5 equiv) in MeCN (anhydrous) (0.2 M). After the addition was complete, the resulting reaction mixture was warmed to room temperature and stirred for 1-16 h. Water was added to the reaction mixture and the resulting suspension was stirred for 1 h. The suspension was filtered and washed with water and Et2O. The residue was dried to give the sulfonamide as a solid.

[0676] Compound A: A solution of compound 7 (1.0 equivalent) in THF (dry) (0.06–0.10 M) was cooled to −78° C. under a nitrogen atmosphere, and a 1M THF solution of LiHMDS (3.0 equivalents) was slowly added. After complete addition, in some cases, the resulting reaction mixture was diluted with some additional tetrahydrofuran (dry) and stirred for 30 min, allowing it to warm to 0° C. This was added dropwise to a cooled (−78° C.) solution of NCS or NBS (1.2 equivalents) in THF (dry) (0.04 M) via a cannula over 15 minutes. The resulting reaction mixture was stirred at −78° C. for 1 hour. The reaction mixture was quenched with 1M HCl at −78° C. and allowed to warm to room temperature. Some additional water was added and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The impure product, compound 7, was used as is.

[0677] Compound B.5: Compound A (1.0 eq) was suspended in MeOH (0.10–0.20 M). An amine (1–10 eq) was added. Optionally, 2–5 eq of Et3N was added, and the reaction mixture was stirred at room temperature for 2–16 h. The reaction mixture was filtered and purified by preparative HPLC (method: acid preparation or base preparation) and lyophilized to yield the desired amine B.5 or Genevac. TM , is a solid.

[0678] Example 2

[0679] Synthesis of compound 244

[0680]

[0681] Compound 244 was prepared in 1 step:

[0682] Step 1: Starting from 4-(chloromethyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and a 2.0 M solution of dimethylamine in MeOH, follow the general synthesis of compound B.5. This product was combined with another batch and purified by column chromatography to afford the title compound as a white solid after freeze-drying.

[0683] 4-((Dimethylamino)methyl)-5-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method T): t R =1.52min; [M+H] + m / z calcd = 525.2, found = 525.2; 1 H NMR (400MHz, DMSO) δ9.37 (s, 1H), 7.26 (t, J = 7.9Hz, 1H), 7.18–7.08 (m, 2H), 6.94 (s, 1H),6.76(s,1H),4.02(s,2H),3.59(s,2H),3.05(s,3H),2.93(s,3H),2.18(s,6H).

[0684] Example 3

[0685] Synthesis of compound 245

[0686]

[0687] Compound 245 was prepared in 1 step:

[0688] Step 1: Starting from 4-(bromomethyl)-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and N-ethylmethylamine, the general synthetic procedure for compound B.5 was followed in DCMDCM. After complete conversion, the reaction was concentrated under reduced pressure. The impure product was purified by column chromatography to afford the title compound as a white solid.

[0689] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((ethyl(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze: LCMS (Method T): t R =1.75min; [M+H] + m / z calcd = 537.0 / 539.0, found = 537.2 / 539.2; 1H NMR (400 MHz, DMSO) δ 9.02 (s, 1H), 8.12 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.29–7.08 (m, 4H), 6.78–6.68 (m, 1H), 4.09 (s, 2H), 3.60 (s, 2H), 3.07 (s, 3H), 2.94 (s, 3H), 2.55 (d, J = 4.2 Hz, 3H), 2.43 (q, J = 7.1 Hz, 2H), 2.10 (s, 3H), 0.98 (t, J = 7.1 Hz, 3H)

[0690] Example 4

[0691] Synthesis of compound 246

[0692]

[0693] Compound 246 was prepared in 2 steps:

[0694] Step 1: Starting from 4-(bromomethyl)-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and N-Boc piperazine, follow the general synthesis of compound B.5. The product is purified by preparative base. The desired fractions are combined and concentrated under reduced pressure to yield the amine as a colorless oil.

[0695] Step 2: Amine was dissolved in 1,4-dioxane (3 mL) and a solution of HCl in dioxane (4 M, 16.7 equivalents) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and co-evaporated twice with DCMDCM. The residue was dissolved in MeCN / water and lyophilized to give the title compound as a white solid.

[0696] 3-(2-Chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate hydrochloride analyze : LCMS (Method T): t R =1.40min; [M+H] +m / z calculated value = 564.1 / 566.1, found value = 564.2 / 566.2; 1H NMR (400 MHz, DMSO) δ 9.00 (s, 1H), 8.73–8.68 (m, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.39 (dd, J = 8.1, 1.5 Hz, 1H), 7.30–7.24 (m, 2H), 7.20–7.12 (m, 2H), 6.77 (d, 1H), 4.07 (s, 2H), 3.75 (s, 2H), 3.07 (s, 3H), 3.00–2.85 (m, 7H), 2.72–2.62 (m, 4H), 2.57 (d, J = 4.7 Hz, 3H).

[0697] Example 5

[0698] Synthesis of compound 249

[0699]

[0700] Compound 249 was prepared in 3 steps:

[0701] Step 1: Following the general synthetic procedure for compound B.5, starting from the bromine compound and a 2.0 M solution of dimethylamine in MeOH, the impure product was purified by column chromatography to afford the title compound as a white solid.

[0702] 3-(2-Chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method R): t R =0.95min; [M+H] + m / z calculated = 522.1, found = 522.2; 1 H NMR (400MHz, DMSO) δ9.69(s,1H),8.09(d,J=8.9Hz,1H),7.33(dd,J=8.0,1.5Hz,1H),7.24(d,J=2.3Hz,1H),7.20–7.07(m,2H),6.85( dd,J=7.8,1.5Hz,1H),4.11(s,2H),3.56(s,2H),3.14(q,J=7.3Hz,2H),3.07(s,3H),2.94(s,3H),2.18(s,6H),1.29(t,J=7.3Hz,3H).

[0703] Example 6

[0704] Synthesis of compound 252

[0705]

[0706] Compound 252 was prepared in 1 step:

[0707] Step 1: Starting with 4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate (50 mg, 0.097 mmol) and a 2.0 M solution of dimethylamine in MeOH, follow the general synthesis of compound B.5. The product was purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0708] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method R): t R =0.89min; [M+H] + m / z calcd = 537.2, found = 537.2; 1 H NMR (400MHz, DMSO) δ9.38(s,1H),7.27(td,J=8.1,1.7Hz,1H),7.16(s,1H),6.99(t,J=7.9Hz,1H),6.84(d,J= 2.3Hz,1H),6.82–6.75(m,2H),4.03(s,2H),3.89(s,3H),3.74(s,2H),3.06(s,3H),2.93(s,3H),2.16(s,6H).

[0709] Example 7

[0710] Synthesis of compound 253

[0711]

[0712] Compound 253 was prepared in 1 step:

[0713] Step 1: Starting from 4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methyl-2-oxo-2H-chromen-7-yl dimethylcarbamate and a 2.0 M solution of dimethylamine in MeOH, follow the general synthesis of compound B.5. The product is purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0714] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methyl-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method R): t R =0.85min; [M+H] + m / z calcd = 521.2, found = 521.2; 1 H NMR (400MHz, DMSO) δ9.36(s,1H),7.28(td,J=7.8,1.6Hz,1H),7.21(q,J=5.0Hz,1H),7.14(d,J=1.7Hz,1H),7.00(t,J=7.9Hz,1H),6.88( d,J=1.7Hz,1H),6.85–6.77(m,1H),4.07(s,2H),3.63(s,2H),3.12(s,3H),2.93(s,3H),2.52(d,J=5.0Hz,3H),2.37(s,3H),2.08(s,6H).

[0715] Example 8

[0716] Synthesis of compound 254

[0717]

[0718] Compound 254 was prepared in 1 step:

[0719] Step 1: Starting from 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-(chloromethyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate and piperazine, follow the general synthesis of compound B.5. The impure product was purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0720] 3-(2-Chloro-3-((N-methylsulfamoyl)amino)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method R): t R =0.98min; [M+H] + m / z calcd = 582.2, found = 582.2; 1H NMR (400MHz, DMSO) δ8.05(d,J=11.7Hz,1H),7.48(d,J=6.8Hz,1H),7.38(dd,J=8.1,1.5Hz,1H),7.13(t,J=7.9Hz,1H),6.74( dd,J=7.8,1.5Hz,1H),4.08(s,2H),3.58(s,2H),3.09(s,3H),2.95(s,3H),2.59(t,J=4.7Hz,3H),2.55(s,3H),2.35(s,4H).

[0721] Example 9

[0722] Synthesis of compound 255

[0723]

[0724] Compound 255 was prepared in 1 step:

[0725] Step 1: Following the general synthetic procedure for compound B.5, starting with bromine and using piperazine, the impure product was purified by column chromatography and lyophilized to afford the title compound as a white solid.

[0726] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-6-fluoro-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method R): t R =1.02min; [M+H] + m / z calcd = 581.2, found = 581.2; 1 H NMR (400MHz, DMSO) δ8.04(d,J=11.7Hz,1H),7.48(d,J=6.9Hz,1H),7.29(dd,J=8.2,1.5Hz,1H),7.04(t,J=7.9Hz,1H),6.61(d,J=7.7Hz,1 H), 4.07 (s, 2H), 3.58 (s, 2H), 3.09 (s, 3H), 3.01 (q, J = 7.3Hz, 2H), 2.95 (s, 3H), 2.61 (t, J = 4.5Hz, 4H), 2.37 (s, 5H), 1.24 (t, J = 7.3Hz, 3H).

[0727] Example 10

[0728] Synthesis of compound 256

[0729]

[0730] Compound 254 was prepared in 1 step:

[0731] Step 1: Starting from 6-chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-(chloromethyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and piperazine, follow the general synthesis of compound B.5. The impure product is purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0732] 6-Chloro-3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yl dimethylcarbamate hydrochloride Analysis: LCMS (Method R): t R =1.02min; [M+H] + m / z calculated = 598.1, found = 598.2; 1 H NMR (400MHz, DMSO) δ9.05 (s, 1H), 8.66 (s, 2H), 8.21 (s, 1H), 7.53 (s, 1H), 7.40 (d, J = 7.9Hz, 1H), 7.30 (d, J = 5.2Hz, 1H), 7.15 (t, J = 7. 9Hz,1H),6.80(d,J=7.8Hz,1H),4.07(s,2H),3.77(s,2H),3.11(s,3H),2.95(s,3H),3.94(s,4H)2.68(s,4H),2.57(d,J=4.5Hz,3H).

[0733] Example 11

[0734] Synthesis of compound 257

[0735]

[0736] Compound 257 was prepared in 3 steps:

[0737] Step 1: Following the general synthetic procedure for compound B.5, starting with bromine and using piperazine, the impure product was purified by column chromatography and lyophilized to afford the title compound as a white solid.

[0738] 6-Chloro-3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate hydrochloride analyze : LCMS (Method R): t R =1.05min; [M+H] +m / z calculated = 597.1, found = 597.2; 1 H NMR (400MHz, DMSO) δ9.48(s,1H),9.04(s,2H),8.23(s,1H),7.53(s,1H),7.34(d,J=8.0Hz,1H),7.17(t,J=7.9Hz,1H),6.89(d,J=7 .7Hz,1H),4.09(s,2H),3.82(s,2H),3.16(q,J=7.4Hz,2H),3.11(s,3H),2.95(d,J=5.5Hz,7H),2.74(s,4H),1.30(t,J=7.3Hz,3H).

[0739] Example 12

[0740] Synthesis of compound 258

[0741]

[0742] Compound 258 was prepared in 3 steps:

[0743] Step 1: Following the general synthetic procedure for compound B.5, starting with bromine and using piperazine, the impure product was purified by column chromatography and lyophilized to afford the title compound as a white solid.

[0744] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-2-oxo-4-(piperazin-1-ylmethyl)-2H-chromen-7-yldimethylcarbamate analyze : LCMS (Method R): t R =1.00min; [M+H] + m / z calcd = 563.2, found = 563.2; 1 H NMR (400MHz, DMSO) δ8.26(s,1H),8.10(d,J=8.9Hz,1H),7.31(d,J=8.1Hz,1H),7.25(d,J=2.3Hz,1H),7.17(dd,J=8.8,2.4Hz,1H),7.11(t,J=7. 9Hz,1H),6.74(d,J=7.7Hz,1H),4.08(s,2H),3.62(s,2H),3.08(d,J=3. 5Hz, 5H), 2.94 (s, 3H), 2.63 (s, 4H), 2.40 (s, 4H), 1.27 (t, J = 7.3Hz, 3H).

[0745] Example 13

[0746] Synthesis of compound 261

[0747]

[0748] Compound 261 was prepared in 1 step:

[0749] Step 1: Using 4-(bromomethyl)-6-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate and N-methylethylamine as raw materials, according to the general synthesis of compound B.5, the product was purified by chromatography and freeze-dried to obtain the title compound as a white solid.

[0750] 4-((Ethyl(methyl)amino)methyl)-6-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method T): t R =1.73min; [M+H] + m / z calculated = 538.6, found = 539.2; 1 H NMR (400MHz, CDCl3) δ7.96 (d, J=11.2Hz, 1H), 7.40 (td, J=7.8, 1.5Hz, 1H), 7 .19(d,J=6.7Hz,1H),7.01(t,J=8.0Hz,1H),6.87(d,J=7.7Hz,1H),6.60(s,1 H),4.42(d,J=5.6Hz,1H),4.15(s,2H),3.63(s,2H),3.15(s,3H),3.05(s,3H ),2.76(d,J=5.3Hz,3H),2.48(s,2H),2.17(s,3H),1.25(s,1H),1.10(s,3H)

[0751] Example 14

[0752] Synthesis of compound 262

[0753]

[0754] Compound 262 was prepared in 2 steps:

[0755] Step 1: Starting from 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and N-Boc piperazine, follow the general synthesis of compound E.5. The product is purified by preparative base. The desired fractions are combined and concentrated under reduced pressure to yield the amine as a colorless oil.

[0756] Step 2: Amine was dissolved in 1,4-dioxane (3 mL) and a solution of HCl in dioxane (4 M, 16.7 equivalents) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and co-evaporated twice with DCMDCM. The residue was dissolved in MeCN / water and lyophilized to give the title compound as a white solid.

[0757] Analysis: LCMS (Method S): t R =1.00min; [M+H] + m / z calculated value = 548.2, found value = 548.2; 1H NMR (400 MHz, DMSO) δ 9.37 (s, 1H), 8.88 (s, 2H), 8.09 (d, J = 8.8 Hz, 1H), 7.32–7.19 (m, 3H), 7.17 (dd, J = 8.9, 2.4 Hz, 1H), 7.00 (t, J = 7.8 Hz, 1H), 6.86–6.78 (m, 1H), 4.04 (s, 2H), 3.86 (s, 2H), 3.07 (s, 3H), 2.95 (d, J = 14.4 Hz, 7H), 2.73 (s, 4H), 2.54 (d, J = 2.8 Hz, 3H).

[0758] Example 15

[0759] Synthesis of compound 263

[0760]

[0761] Compound 263 was prepared in 1 step:

[0762] Step 1: Starting with 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and 2-fluoro-N-methylethan-1-amine, follow the general synthesis of compound B.5. The product is purified by column chromatography and freeze-dried to yield the title compound as a white solid.

[0763] 3-(2-Fluoro-3-((N-methylsulfamoyl)amino)benzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method R): t R =1.22min; [M+H] + m / z calcd = 539.2, found = 539.2; 1H NMR (400MHz, DMSO) δ8.12(d,J=8.9Hz,1H),7.31–7.22(m,2H),7.14(dd,J=8.9,2.4Hz,1H),6.99(t,J=7.9Hz,1H),6.81(s,1H),4.59(t,J=4.7 Hz,1H),4.47(t,J=4.7Hz,1H),4.05(s,2H),3.80(s,2H),3.06(s,3H),2.93(s,3H),2.79(t,J=4.8Hz,1H),2.71(t,J=4.8Hz,1H),2.19(s,3H).

[0764] Example 16

[0765] Synthesis of compound 264

[0766]

[0767] Compound 264 was prepared in 3 steps:

[0768] Step 1: Following the general synthetic procedure for compound B.5, starting from bromine and 2-fluoro-N-methylethan-1-amine, after complete conversion, the impure product was purified by column chromatography to afford the title compound as an off-white solid.

[0769] 3-(3-(Ethylsulfonamido)-2-fluorobenzyl)-4-(((2-fluoroethyl)(methyl)amino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method R): t R =1.32min; [M+H] + m / z calcd = 538.2, found = 538.2; 1 H NMR (400MHz, DMSO) δ9.60 (s, 1H), 8.12 (d, J = 8.9Hz, 1H), 7.29–7.18 (m, 2H), 7.14 (dd, J=8.8,2.3Hz,1H),7.01(t,J=8.0Hz,1H),6.90(t,J=7.4Hz,1H),4.58(t,J=4.8Hz,1H ),4.46(t,J=4.8Hz,1H),4.06(s,2H),3.81(s,2H),3.08(d,J=13.3Hz,5H),2.93(s,3 H), 2.78 (t, J = 4.7Hz, 1H), 2.71 (t, J = 4.7Hz, 1H), 2.18 (s, 3H), 1.26 (t, J = 7.3Hz, 3H).

[0770] Example 17

[0771] Synthesis of compound 265

[0772]

[0773] Compound 265 was prepared in 1 step:

[0774] Step 1: Starting with 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and N-methylprop-2-yn-1-amine, follow the general synthesis of compound B.5. The product is purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0775] Example 18

[0776] Synthesis of compound 266

[0777]

[0778] Compound 266 was prepared in 1 step:

[0779] Step 1: Starting with 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate and 2,2-difluoro-N-methylethan-1-amine, follow the general synthesis of compound B.5. The product was purified by column chromatography and freeze-dried to yield the title compound as a white solid.

[0780] 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate Analysis: LCMS (Method R): t R =1.64min; [M+H] + m / z calcd = 557.2, found = 557.2; 1 H NMR(400MHz, DMSO)δ9.41(s,1H),8.09(d,J=8.9Hz,1H),7.38–7.23(m,2H),7.14(dd,J=8.8,2.4Hz,2H),6.98(t, J=8.0Hz,1H),6.79(s,1H),6.11(t,1H),4.05(s,2H),3.89(s,2H),3.06(s,3H),2.96–2.80(m,5H),2.24(s,3H).

[0781] Example 19

[0782] Synthesis of compound 267

[0783]

[0784] Compound 267 was prepared in 3 steps:

[0785] Step 1: Following the general synthetic procedure for compound B.5, starting from 220 mg, 0.384 mmol of bromine and 2,2-difluoro-N-methylethan-1-amine, after complete conversion, the impure product was purified by column chromatography to afford the title compound as an off-white solid.

[0786] 4-(((2,2-difluoroethyl)(methyl)amino)methyl)-3-(3-(ethylsulfonamido)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method R): t R =1.69min; [M+H] + m / z calculated = 556.2, found = 556.4; 1 H NMR (400MHz, DMSO) δ9.62(s,1H),8.09(d,J=8.9Hz,1H),7.24(q,J=3.0Hz,2H),7.14(dd,J=8.9,2.4Hz,1H),7.01(t,J=7.9Hz,1H),6.89( t,J=7.1Hz,1H),6.31–5.93(m,1H),4.06(s,2H),3.90(s,2H),3.17–3.02(m,5H),2.99–2.80(m,5H),2.24(s,3H),1.26(t,J=7.3Hz,3H).

[0787] Example 20

[0788] Synthesis of compound 268

[0789]

[0790] Compound 268 was prepared in 1 step:

[0791] Step 1: Starting with 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (45 mg, 0.075 mmol, py: 40%) and 2-(methylamino)acetonitrile, following the general synthesis of compound B.2, 3.0 equivalents of Net3 were added. The product was purified by preparing the base followed by the acid and lyophilized to afford the title compound (3.8 mg, 0.007 mmol, py: 21%) as a white solid.

[0792] Example 21

[0793] Synthesis of compound 269

[0794]

[0795] Compound 269 was prepared in 1 step:

[0796] Step 1: Starting from 4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-5-methoxy-2-oxo-2H-chromen-7-yl dimethylcarbamate and a 2.0 M solution of dimethylamine in MeOH, follow the general synthesis of compound B.5. The product is purified by column chromatography and freeze-dried to give the title compound as a white solid.

[0797] Example 22

[0798] Synthesis of compound 271

[0799]

[0800] Compound 271 was prepared in 1 step:

[0801] Step 1: Under an inert atmosphere, to a solution of 3-(3-bromo-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (2.0 g, 4.19 mmol, 1.0 equiv) and (tributylstannyl)methanol (1.614 g, 5.03 mmol) in 1,4-dioxane (0.1 M) (1.61 g, 5.03 mmol, 1.2 equiv) was added Pd(Ph3p)4 (0.242 g, 0.209 mmol, 0.05 equiv). The resulting reaction mixture was stirred at 100 ° C for 18 hours. The reaction mixture was filtered and washed with MeCN. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography using the "Flash" method (heptane / EtOAc = 1:0 → 2:8). 40 mg of the still impure product was purified by preparative base to afford the title compound (29 mg, 0.067 mmol, yield: 1.5%) as an off-white solid. Yield : The title compound was isolated as an off-white solid (1% over 1 step)

[0802] 4-((Dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method T): t R =1.53min; [M+H] + m / z calculated value = 429.2, found value = 429.2; 1H NMR (400 MHz, DMSO) δ 8.07 (d, J = 8.8 Hz, 1H), 7.33–7.27 (m, 1H), 7.22 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 8.8, 2.4 Hz, 1H), 7.08–6.96 (m, 2H), 5.23 (t, J = 5.7 Hz, 1H), 4.55 (d, J = 5.5 Hz, 2H), 4.04 (s, 2H), 3.65 (s, 2H), 3.06 (s, 3H), 2.93 (s, 3H), 2.19 (s, 6H).

[0803] Example 23

[0804] Synthesis of compound 272

[0805]

[0806] Compound 272 was prepared in 1 step:

[0807] Step 1: Starting with 4-(bromomethyl)-3-(3-((ethylsulfonyl)methyl)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (45 mg, 0.075 mmol, py: 40%) and dimethylamine, following the general synthesis of compound B.2, 3.0 equivalents of Net3 were added. The product was purified by preparing the base followed by the acid and lyophilized to afford the title compound (3.8 mg, 0.007 mmol, py: 21%) as a white solid.

[0808] Yield: Compound 272 was isolated as a white solid (21% over 1 step).

[0809] Example 24

[0810] Synthesis of compound 273

[0811]

[0812] Compound 273 was prepared in 3 steps:

[0813] Step 1: Under an inert atmosphere, to a solution of 3-(3-bromo-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (2.0 g, 4.19 mmol, 1.0 equiv) and (tributylstannyl)methanol (1.614 g, 5.03 mmol) in 1,4-dioxane (0.1 M) (1.61 g, 5.03 mmol, 1.2 equiv) was added Pd(Ph3p)4 (0.242 g, 0.209 mmol, 0.05 equiv). The reaction mixture was stirred at 100 ° C for 18 hours. The reaction mixture was filtered and washed with MeCN. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography using the "flash" method (heptane / EtOAc = 1:0 → 2:8). The desired fractions were combined and concentrated under reduced pressure to give 4-((dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (1.46 g, 3.3 mmol, yield: 79%) as a clear oil.

[0814] Step 2: To a solution of 4-((dimethylamino)methyl)-3-(2-fluoro-3-(hydroxymethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (1.41 g, 3.29 mmol, 1.0 equiv) in DCM (0.23 M) was slowly added a solution of thionyl chloride (0.48 ml, 6.58 mmol, 2.0 equiv) in DCM (2 ml) at 0°C. The resulting reaction mixture was stirred for 1 hour and allowed to warm to room temperature. The reaction mixture was concentrated under reduced pressure and stripped twice with DCM to give 3-(3-(chloromethyl)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (1.68 g, 3.60 mmol, 109% yield) as an off-white solid.

[0815] Step 3: To a mixture of 3-(3-(chloromethyl)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (0.5 g, 1.12 mmol, 1.0 eq) in ethanol (Abs) (0.1 M) was added thiourea (0.102 g, 1.343 mmol, 1.2 eq) under N2 atmosphere. The reaction mixture was stirred at 80°C for 2 hours and then at room temperature for 2 days. NaOH 2N (1.68 ml, 3.36 mmol, 3.0 eq) was added and stirred at 80°C for 2 hours. The reaction mixture was acidified with 1 M HCl. Some additional water was added followed by DCM. The layers were separated using a phase separator, and the organic layer was concentrated under reduced pressure to give 4-((dimethylamino)methyl)-3-(2-fluoro-3-(mercaptomethyl)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate and its dimer ((((disulfanediylbis(methylene))bis(2-fluoro-3,1-phenylene))bis(methylene))bis(4-((dimethylamino)methyl)-2-oxo-2H-chromen-3,7-diyl)bis(dimethylcarbamate)) (570 mg, 0.67 mmol, 60% yield) as a yellow solid.

[0816] Step 4: (((disulfanediylbis(methylene))bis(2-fluoro-3,1-phenylene))bis(methylene))bis(4-((dimethylamino)methyl)-2-oxo-2H-chromen-3,7-diyl)bis(dimethylcarbamate) (0.57 g, 0.257 mmol, 1.0 eq) was dissolved in THF (0.11 M) / water (0.11 M) and cooled to 0 ° C. Tri-n-butylphosphine (0.071 ml, 0.283 mmol, 1.1 eq) was slowly added and stirred at room temperature for 1 hour. Water and DCM were added and the layers were separated by phase separator. The organic layer was concentrated under reduced pressure and the residue was purified by column chromatography using the "Flash" method (DCM / MeOH = 1:0→98:2). The desired fractions were combined and concentrated under reduced pressure to give 4-((dimethylamino)methyl)-3-(2-fluoro-3-(mercaptomethyl)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (283 mg, 0.618 mmol, 55% yield) as a clear oil.

[0817] Step 5: 4-((dimethylamino)methyl)-3-(2-fluoro-3-(mercaptomethyl)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (50 mg, 0.112 mmol, 1.0 eq) was dissolved in DMF (dry) (0.23 M), CsCO (36.6 mg, 0.112 mmol, 1.0 eq) and iodoethane (10.91 μl, 0.135 mmol, 1.2 eq) were added and stirred at room temperature for 1 hour. Iodoethane (1.818 μl, 0.022 mmol, 0.2 eq) was added and stirred at room temperature for 30 minutes. Water was added to the reaction mixture and the product was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give 4-((dimethylamino)methyl)-3-(3-((ethylthio)methyl)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (43 mg, 0.058 mmol, yield: 52%) as a yellow oil.

[0818] Step 6: 4-((Dimethylamino)methyl)-3-(3-((ethylthio)methyl)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (43 mg, 0.091 mmol, 1.0 equiv) was dissolved in MeOH (0.06 M) / water (0.06 M), potassium bisulfate was added, monopersulfate compound (55.9 mg, 0.091 mmol, 1.0 equiv) was added and stirred at room temperature for 1 hour. Water was added to the reaction mixture and the product was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The impure product was purified by making a base followed by making an acid to give the title compound (6.5 mg, 0.012 mmol, 14% yield) as a white solid.

[0819] 4-((Dimethylamino)methyl)-3-(3-((ethylsulfonyl)methyl)-2-fluorobenzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method T): t R =1.60 min; [M+H]+m / z calcd. =505.2, found =505.2; 1H NMR (400 MHz, DMSO) δ8.08 (d, J=8.8 Hz, 1H), 7.35–7.27 (m, 1H), 7.22 (d, J=2.4 Hz, 1H), 7.18–7.04 (m, 3H), 4.52 (s, 2H), 4.07 (s, 2H), 3.65 (s, 2H), 3.12 (q, J=7.5 Hz, 2H), 3.06 (s, 3H), 2.93 (s, 3H), 2.18 (s, 6H), 1.25 (t, J=7.4 Hz, 3H).

[0820] Example 25

[0821] Synthesis of compound 274

[0822]

[0823] Compound 274 was prepared in 1 step:

[0824] Step 1: 3-(3-Bromo-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate (50 mg, 0.105 mmol, 1.0 equiv) was dissolved in toluene (dry) (0.2 M) and flushed with argon. Pd(dba) (4.80 mg, 5.24 μmol, 0.05 equiv), t-BuXPhos (8.90 mg, 0.021 mmol, 0.2 equiv), KCO (29.0 mg, 0.209 mmol, 2.0 equiv) and 2-methylpropane-2-sulfenamide (25.4 mg, 0.209 mmol, 2.0 equiv) were then added. The resulting reaction mixture was stirred at 50° C. for 17 hours. The reaction mixture was flushed with argon and Pd2(dba)3 (4.80 mg, 5.24 μmol, 0.05 eq) and t-BuXPhos (8.90 mg, 0.021 mmol, 0.2 eq) were added. The reaction mixture was stirred at 50°C for 48 hours. The impure product was purified by preparative base to give the title compound (40 mg, 0.076 mmol, yield: 72.7%) as a white solid. Yield : The title compound was isolated as a white solid (73% over 1 step).

[0825] 3-(3-((tert-Butylsulfinyl)amino)-2-fluorobenzyl)-4-((dimethylamino)methyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method T): t R =1.70min; [M+H] + m / z calculated value = 518.2, found value = 518.2; 1H NMR (400 MHz, DMSO) δ 8.08 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 7.22 (d, J = 2.3 Hz, 1H), 7.17–7.06 (m, 2H), 6.97 (t, J = 7.8 Hz, 1H), 6.76 (t, J = 7.0 Hz, 1H), 4.04 (s, 2H), 3.65 (s, 2H), 3.06 (s, 3H), 2.93 (s, 3H), 2.18 (s, 6H), 1.25 (s, 9H).

[0826] Example 26

[0827] Synthesis of compound 278

[0828]

[0829] Compound 278 was prepared in 1 step:

[0830] Step 1: Starting from 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-(chloromethyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate and a 2.0 M solution of dimethylamine in MeOH, follow the general synthesis of compound B.5. The impure product is purified by preparative base and lyophilized to afford the title compound as a white solid.

[0831] 3-(2-chloro-3-((N-methylsulfamoyl)amino)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method T): t R =2.84min; [M+H] + m / z calcd = 541.0 / 543.0, found = 541.3 / 543.2; 1 H NMR (400MHz, DMSO) δ9.00(s,1H),8.01(d,J=11.7Hz,1H),7.48(d,J=6.8Hz,1H),7.41–7.36(m,1H),7.13(t,J=7.9H z,1H),6.74(d,J=7.8Hz,1H),4.09(s,2H),3.54(s,2H),3.09(s,3H),2.95(s,3H),2.57–2.53(m,3H),2.18(s,6H).

[0832] Example 27

[0833] Synthesis of compound 279

[0834]

[0835] Compound 279 was prepared in 1 step:

[0836] Step 1: Following the general synthetic procedure for compound B.5, starting from bromine, use a 2.0 M solution of dimethylamine in MeOH. The impure product is purified by column chromatography and lyophilized to afford the title compound as a white solid.

[0837] 3-(2-chloro-3-(ethylsulfonamido)benzyl)-4-((dimethylamino)methyl)-6-fluoro-2-oxo-2H-chromen-7-yl dimethylcarbamate analyze : LCMS (Method T): t R =3.03min; [M+H] + m / z calcd = 540.0 / 542.0, found = 540.2 / 542.2;1 H NMR (400MHz, DMSO) δ9.45(s,1H),8.01(d,J=11.7Hz,1H),7.48(d,J=6.9Hz,1H),7.33(dd,J=8.0,1.5Hz,1H),7.15(t,J=7.9Hz,1H),6 .84(d,J=7.7Hz,1H),4.10(s,2H),3.55(s,2H),3.13(q,J=7.2Hz,2H),3.09(s,3H),2.95(s,4H),2.17(s,7H),1.28(t,J=7.3Hz,4H).

[0838] Example 28

[0839] Synthesis of compound 280

[0840]

[0841] Compound 280 was prepared in 1 step:

[0842] Step 1: Starting from 3-(2-chloro-3-((N-methylsulfamoyl)amino)benz...

Claims

1. A compound having a chemical structure of formula (IV) or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, fluorine or chlorine; R 13 Ethyl or -NR A R B , where R A is hydrogen and R B is methyl; Z2 is -NR 5 R 5’ , R 5 is a C1 to C6 alkyl group; and R 5’ It is a C1 to C6 alkyl group.

2. The compound according to claim 1, wherein R 5 It is methyl.

3. The compound according to claim 2, wherein R 5’ It is methyl.

4. The compound according to claim 2, wherein R 5’ It is ethyl.

5. A compound according to any one of claims 1 to 4, wherein Z2 is -NR 5 R 5’ .

6. The compound according to claim 5, wherein R 13 For-NR A R B .

7. The compound according to claim 6, wherein the compound is or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 6, wherein the compound is or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 6, wherein the compound is or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 6, wherein the compound is or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 6, wherein the compound is Or, or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 6, wherein the compound is or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 5, wherein R 13 It is ethyl.

14. The compound according to claim 11, wherein the compound is or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 11, wherein the compound is or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 11, wherein the compound is or a pharmaceutically acceptable salt thereof.

17. A compound according to any one of claims 1 to 4, wherein Z2 is 18. The compound according to claim 17, wherein R 13 It is ethyl.

19. The compound according to claim 18, wherein the compound is or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 18, wherein the compound is or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 18, wherein the compound is or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 17, wherein R 13 For-NR A R B .

23. The compound according to claim 22, wherein the compound is or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 22, wherein the compound is or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 22, wherein the compound is or a pharmaceutically acceptable salt thereof.

26. A compound according to any one of claims 1 to 4, wherein Z2 is 27. The compound according to claim 26, wherein R 13 It is ethyl.

28. The compound according to claim 26, wherein R 13 For-NR A R B .

29. The compound according to claim 28, wherein the compound is or a pharmaceutically acceptable salt thereof.

30. The compound according to claim 28, wherein the compound is or a pharmaceutically acceptable salt thereof.

31. The compound according to claim 28, wherein the compound is or a pharmaceutically acceptable salt thereof.

32. A compound having a structure of formula (III): including pharmaceutically acceptable salts thereof, in, R 2 is L; R 6 Selected from the group consisting of H or fluorine, chlorine or bromine; R 7 is H; R 13 The invention is selected from the group consisting of optionally substituted optionally substituted amine, C1 to C6 alkyl, H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl and L; R 3 for chlorine; X is –O–; Y is L is –Z1-Z2; Z1 is –CH2–; and Z2 is selected from the group consisting of: –NR 5 R 5′ , optionally substituted C3 to C8 heterocyclyl, –CH2–, –O–, –S–, S═O, –SO2–, C═O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–,–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 , –SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –, –(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 Aryl, optionally substituted C3 to C 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and Each R 5 and R 5′ Independently selected from optionally substituted C1 to C6 alkyl.

33. The compound according to claim 32, wherein Z2 is -NR 5 R 5′ .

34. The compound according to claim 33, wherein R 5 It is methyl.

35. The compound according to claim 34, wherein R 5’ It is methyl.

36. The compound according to claim 34, wherein R 5’ It is ethyl.

37. The compound according to claim 32, wherein Z2 is 38. The compound according to claim 32, wherein Z2 is optionally substituted Where n is 1, 2, 3 or 4.

39. The compound of claim 38, wherein n is 1.

40. A compound according to any one of claims 32 to 39, wherein R 13 For-NR A R B , where R A and R B are each independently selected from hydrogen or C 1-6 alkyl.

41. The compound according to claim 40, wherein R A is hydrogen and R B It is methyl.

42. A compound according to any one of claims 32 to 39, wherein R 13 It is a C1 to C6 alkyl group.

43. The compound according to claim 43, wherein R 13 It is ethyl.

44. according to the compound described in any one of claims 32 to 43, wherein R 6 For fluorine.

45. A compound according to any one of claims 32 to 43, wherein R 6 For chlorine.

46. ​​A compound according to any one of claims 32 to 43, wherein R 6 For H.

47. A compound having a structure of formula (III): including pharmaceutically acceptable salts thereof, in, R 2 is L; R 6 Selected from the group consisting of H or fluorine, chlorine or bromine; R 7 is H; R 13 is a C1 to C6 alkyl group; R 3 for chlorine; X is –O–; Y is L is –Z1-Z2; Z1 is –CH2–; Z2 is –NR 5 R 5′ ;and Each R 5 and R 5′ Independently selected from optionally substituted C1 to C6 alkyl.

48. A compound having a structure of formula (III): including pharmaceutically acceptable salts thereof, in, R 2 The invention is selected from the group consisting of halogen, H, deuterium, hydroxyl, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl and L; R 6 [0043] The present invention is selected from the group consisting of H, halogen, deuterium, hydroxyl, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl and L; R 7 The invention is selected from the group consisting of deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl and L; R 13 The invention is selected from the group consisting of optionally substituted C1 to C6 alkyl, optionally substituted amino, H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted C-amide, optionally substituted N-amide, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamoyl, optionally substituted N-thiocarbamoyl, optionally substituted N-carbamoyl, optionally substituted O-carbamoyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl and L; R 3 is chlorine, bromine or iodine; X is –O–, C(R 5 )2、CH(R 5 )、CH2、 Y is C(R 5 )2、CH(R 5 )、CH2、–O–、 L is –Z1-Z2 or –Z1-Z2-Z3; Z1 is selected from the group consisting of –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–,–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 , –SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –, –(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); Z2 is selected from the group consisting of: –NR 5 R 5′ , –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–,–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 , –SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –, –(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); Z3 is selected from the group consisting of –CH2–, –O–, –S–, S=O, –SO2–, C=O, –CO2–, –NO2, –NH–, –CH2CCH, –CH2CN, –NR 5 R 5′ , –NH(CO)–, –(CO)NH–, –(CO)NR 5 R 5′ –, –NH-SO2–, –SO2-NH–, –R 5 CH2–, –R 5 O–,–R 5 S–, R 5 -S=O、–R 5 SO2–, R 5 -C=O、–R 5 CO2–,–R 5 NH–,–R 5 NH(CO)–,–R 5 (CO)NH–,–R 5 NH-SO2–,–R 5 SO2-NH–, -NHCH2CO-, –CH2R 5 –, –OR 5 –, –SR 5 –、S=OR 5 , –SO2R 5 –、C=OR 5 , –CO2R 5 –, –NHR 5 –, –NH(CO)R 5 –, –(CO)NHR 5 –, –NH-SO2R 5 –, –SO2-NHR 5 -, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C 10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C8 10 heteroaryl, -CH2-(optionally substituted aryl), -CH2-(optionally substituted C3 to C8 cycloalkyl), and -CH2-(optionally substituted C3 to C8 cycloalkyl). 10 heteroaryl); and Each R 5 and R 5′ independently selected from optionally substituted C1 to C6 alkyl, H, deuterium, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C 10 aryl, an optionally substituted C3 to C8 heterocyclic group, and an optionally substituted C3 to C8 10 Heteroaryl.

49. A compound selected from the list consisting of:

50. A compound selected from the list consisting of:

51. A pharmaceutical composition comprising a compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof.

52. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1 to 50 or a pharmaceutical composition thereof.

53. Use of a compound according to any one of claims 1 to 50 for the treatment of cancer.